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Objectives: To formulate a safe, stable, bioadhesive and non-aqueous aspirin gel 
plaster for treatment of localized pain and itch.  
 
Methods: Aspirin plasters were prepared from copolymer of N-vinylacetamide and 
sodium acrylate, anhydrous aluminum chloride, propylene glycol (PG) and N-methyl-
2-pyrrolidone (NMP) by a casting method. The rheological properties of the polymer-
drug matrix gels were studied using oscillatory rheometry. The bioadhesive properties 
of the plasters were studied using an in vitro tensile testing method and an in vivo 
adhesion scoring method on pigs. In vitro drug release through synthetic membranes 
and permeation through pig and human skins were compared using vertical Franz 
diffusion cells. Accelerated stability testing was carried out to determine the stability 
of aspirin in the plasters. In vivo skin irritation studies of the plasters on pigs were 
carried out with laser Doppler perfusion imager (LDPI) and visual analogue scoring 
(VAS) methods. Formulation variables including polymer concentration, ratio of 
polymer to cross-linking agent and ratio of PG to NMP were studied and optimized 
with respect to the above mentioned properties. 
 
Results: The rheological studies showed that storage modulus values were higher than 
loss modulus values, loss tangent values were less than 1 and independent of 
oscillatory frequency, indicating that all the polymer-drug matrix gels were well cross-
linked. The maximum bioadhesion was exhibited by polymer concentration of 9%, 
polymer to cross-linking agent ratio of 1.5:1 and PG to NMP ratio of 2:1. The drug 
release and permeation were decreased with increase in amounts of polymer, cross-
 xii
 
linking agent and propylene glycol in the plaster. No significant difference was found 
between drug permeation through pig skin and human skin. Skin irritation, which was 
not strong enough to be detected visually, was measured quantitatively with LDPI. The 
LDPI results were increased with increasing amounts of solvent mixture and cross-
linking agent in the formulations. VAS and LDPI results showed enhancement of skin 
irritation with increase in aspirin content and duration of application of plasters. The 
accelerated stability testing showed that aspirin was stable in the plasters and no 
statistically significant changes in physical properties and drug content of the plasters 
were observed over the period of storage. 
 
Conclusion: The formulation variables showed significant effects on the rheological 
and bioadhesive properties of the plasters, drug release and permeation, and skin 
irritation reaction. Increased concentration of polymer, cross-linking agent or 
propylene glycol resulted in stronger and denser gels and thereby, slower drug release 
and permeation as well as reduced bioadhesion. The higher proportions of cross-
linking agent and solvent caused skin irritation after repeated prolong contact with the 
skin. It was found that the optimized composition consisting of polymer concentration 
of 9%, polymer to cross-linking agent ratio of 1.5:1 and PG to NMP ratio of 2:1 is the 
most suitable polymer-drug matrix gel formulation for a safe and stable aspirin plaster 







A. Chemical properties of aspirin and its new indications 
1. Chemical properties of aspirin 
Aspirin (o-acetylsalicylic acid) is an odorless, colorless or white crystalline powder 
with a slightly acidic taste. It is slightly soluble in water, freely soluble in alcohol and 
soluble in ether. It is a weak acid with a pKa of 3.6 and a melting point of 143ºC 
(British Pharmacopoeia, 2000) (Figure 1a). Aspirin is stable in dry air but in contact 
with moisture it degrades by hydrolysis to acetic acid and salicylic acid. Although 
aspirin and salicylates are rapidly absorbed from the stomach and duodenum following 
oral administration, the fraction of the administered dose reaching the systemic 
circulation ranges from 50 to 75% (Rowland et al., 1972; Pedersen and FitzGerald, 
1984) due to their extensive first-pass metabolism. Aspirin with plasma half-life of 
14−19 min is rapidly cleared from the plasma. Aspirin is partially hydrolyzed to 
salicylic acid (Figure 1b) during absorption and is distributed to all body tissues and 
fluids, including fetal tissues, breast milk and central nervous system. 
 
All salicylates have analgesic, antipyretic, anti-inflammatory and anti-rheumatic 
effects. They lower elevated body temperature through vasodilatation of peripheral 
vessels, thus enhancing dissipation of excess heat. The anti-inflammatory and 
analgesic activity may be mediated through inhibition of the prostaglandin synthetase 





















potently inhibits prostaglandin synthesis, has greater anti-inflammatory effects and 
irreversibly inhibits platelet aggregation. Single analgesic aspirin dose prolongs 
bleeding time by inhibiting platelet aggregation (Roth and Majerus, 1975; Roth and 
Siok, 1978; Roth et al., 1978). Because of its broad spectrum of indications, rapid 
absorption from the upper gastrointestinal tract and extensive distribution throughout 
the body fluids following oral administration, aspirin is the most widely prescribed 
drug for the treatment of pain, fever, myocardial infarction, atrial fibrillation, angina, 
ischemic stroke and coronary artery bypass grafts (Antiplatelet Trialists’ 
Collaboration, 1994; Hennekens, 1997). Oral dosage of 325 to 650 mg every 4 h is 
needed for minor aches and pains and up to 500 mg every 3 h or 1000 mg every 6 h for 
some extra strength. Therapeutic salicylate level is 150−300 µg/ml (Martindale, 1996). 
 
However, oral administration of aspirin is limited due to its gastrointestinal toxicity 
(McAdam et al., 1995). Other adverse reactions of aspirin are drug allergy, renal 
irritation, aggravation of chronic urticaria, fetal malformations in early pregnancy, 
metabolic acidosis in children and respiratory alkalosis in adults. To avoid these side 
effects and pre-systemic loss of the drug, alternative routes of administration have been 
considered. Particularly, percutaneous delivery of aspirin is attractive due to its new 
indication in the treatment of acute herpetic neuralgia (AHN), post herpetic neuralgia 
(PHN) and pruritus.  
 
2.  New indications of aspirin 
Herpes zoster, also known as shingles or zoster, is a viral infection caused by the 
varicella-zoster virus, which is the virus that causes chickenpox. The symptom of 
zoster is burning pain, tingling or extreme sensitivity in one area of the skin usually 
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limited to one side of the body. There may also be fever or headache. The pain may 
last longer. It is unusual but possible to have pain without blisters or blisters without 
pain. Treatment for shingles includes oral administration of antiviral drugs, steroids, 
antidepressants, anticonvulsants and analgesic agents. The severity and duration of an 
attack of shingles can be significantly reduced by immediate treatment with the 
antiviral drugs such as acyclovir, valacyclovir and famcyclovir. These drugs may also 
help stave off the painful aftereffects of shingles, i.e., post herpetic neuralgia. A 
symptom of post herpetic neuralgia is constant pain or periods of pain that can 
continue after the skin has healed. It can last for months or even years and is more 
common in older people.  
 
There is still inadequate knowledge about the mechanisms of neuropathic pain in 
general, and of herpetic pain in particular. There is a limited range of proven therapies 
effective in relieving the pain of AHN and PHN. Although a wide variety of treatments 
have been claimed to be effective in AHN and to prevent and/or control PHN, limited 
success and/or side effects (e.g., anticholinergic effects of tricyclic antidepressants) can 
generally be expected after trying to relieve acute herpetic and post herpetic pain. 
Topical applications of various preparations such as capsaicin, analgesic cream 
(EMLA), lidocaine cream or patch, aspirin/chloroform mixture and indomethacin 
cream have been reported to be effective in relieving the pain of AHN and PHN 
(Yosipovitch et al., 2001). De Benedittis et al. (1992) studied a double-blind controlled 
clinical trial with aspirin/diethyl ether mixture in the treatment of acute and post 
herpetic neuralgia. The successful results from non-controlled study proved that topical 
application of aspirin in chloroform mixture alleviated pain in post herpetic neuralgia 
(King, 1993). 
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Itch, also known as pruritus, is defined as an unpleasant sensation on the skin that 
provokes the desire to rub or scratch the area to obtain relief. Itch can cause discomfort 
and frustration. In severe cases, it can lead to disturbed sleep, anxiety and depression. 
There are numerous causes of pruritus. Basically, they can be classified under the 
following 4 main headings: (1) skin disease such as eczema, (2) systemic diseases such 
as chronic renal failure, (3) damage to nerve fibers such as post herpetic itch, and (4) 
psychiatric itch such as delusions of parasitosis. Itch can also be classified as localized 
and generalized. Lichen simplex chronicus (LSC) or localized circumscribed 
neurodermatitis is a troublesome type of itchy dermatosis, characterized by chronic 
itching and scratching as well as a self-perpetuating scratch-itch cycle. The persistent 
scratching causes formation of thick and leathery hyper-pigmented skin (excoriation, 
lichenification) and reduces the effectiveness of the skin as a major protective barrier. 
Therefore, itch and lichenification constitute its hallmark and seem to be more 
common in Asians (Marks, 1999; Tianco et al., 1991; Yap et al., 1994). 
 
The primary treatment of itch is to stop the itch scratch cycle. This may include 
counseling to become aware of the importance of not scratching, stress management 
measures or behavior modification. Antihistamines, sedatives or tranquilizers may be 
needed to reduce itching and stress. However, the treatment of lichen simplex 
chronicus is a challenge to the dermatologist since topical treatments using high 
potency steroids were not effective (Marks, 1999). It was reported that topically 
applied aspirin rapidly decreased histamine induced itch (Yosipovitch et al., 1996). 
Recently, a double-blind crossover placebo-controlled trial was conducted with 29 
patients suffering from lichen simplex chronicus to assess the effect of topical 
administration of aspirin/dichloromethane solution and it was concluded that topical 
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aspirin/dichloromethane solution might be a practical, safe and efficient method for the 
treatment of lichen simplex chronicus (Yosipovitch et al., 2001). Unfortunately, the 
formulation of topical aspirin was not stable because of the usage of volatile solvent. A 
stable topical preparation of aspirin would be an excellent option for the treatment of 
lichen simplex chronicus and other localized itch. Salicylic acid, the degradation 
product of aspirin, is also widely used as a topical therapeutic agent for psoriasis, 
ichthyosis and acne because of its keratolytic action and permeability through healthy 
skin (Schwarb et al., 1999). 
 
B. Percutaneous drug delivery systems 
1. Physiology of the skin 
The skin is principally composed of two parts, namely the outer epidermis and the 
inner dermis. The dermis contains capillaries, sebaceous and sweat glands, hair 
follicles and nerves; the epidermis, on the other hand, is avascular. The epidermis has a 
multilamellar structure that represents the different stages of cell differentiation. By 
moving upwards from the proliferative basal layer, the cells change in an ordered 
fashion from metabolically active and dividing cells to dense, functionally dead and 
keratinized cells, corneocytes. These keratinized cells are surrounded by multilamellar 
lipid bilayers and constitute the unique “brick and motar” structure of the outer 10−20 
µm of the epidermis, called the stratum corneum. The bricks composed of the keratin 
rich corneocytes are embedded in a ‘mortar’ composed of multiple lipid bilayers 
consisting of ceramides, fatty acids, cholesterol and cholesterol esters. These bilayers 
form regions of semicrystalline, gel and liquid crystals domains. The intact stratum 
corneum provides the main barrier to permeability of substances due to its unique 
‘brick and mortar’ structure. The lipophilic nature of the intercellular lipids limits the 
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permeability of hydrophilic and large molecules of peptide and protein drugs in the 
skin. Drugs have three potential pathways through the skin, namely intercellular route, 
transcellular route and appendages route. The skin appendages occupy only 0.1% of 
the total human skin surface and the contribution of this pathway is usually considered 
to be small. Drug permeation through the skin is mainly though the intercellular lipid 
route. The penetration enhancers mainly act on the intercellular lipids (Moser et al., 
2001) (Figure 2). 
 
2. Types of percutaneous drug delivery systems 
Based on the target of action, percutaneous drug delivery systems are divided into 
topical, regional and transdermal delivery. Topical delivery can be defined as the 
application of a drug-containing formulation to the skin to directly treat cutaneous 
disorders or the cutaneous manifestations of a general disease. The delivery systems 
are placed against the skin to deliver drugs to the local tissues immediately beneath the 
application site. Active ingredients may or may not require intracutaneous penetration 
and deposition. Regional delivery system, on the other hand, is placed against the skin 
to deliver drugs to deep regions in the vicinity of, but still somewhat remote from, the 
application site. It involves the application of a drug to the skin for the purpose of 
treating diseases or alleviating disease symptoms in deep tissues beneath the 
application site. Topical and regional delivery systems are open applications and may 









Figure 2. Drug transport through human skin (Moser et al., 2001) 
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The application techniques and the amounts of usage for topical and regional delivery 
systems are highly specific and they can be applied only on diseased, damaged skin. 
They are short-acting applications, with drug level in the local tissues related to 
product efficacy. Systemic absorption is absolutely undesirable, although, some are 
unavoidable. By removal of system, the application can be interrupted without 
affecting tissue wear and tear. Only small fraction of total drug is delivered from 
dermatological formulations. Transdermal delivery system (TDDS) is placed against 
the skin to deliver drugs to the systemic circulation to mediate pharmacological 
changes somewhere totally remote from the application site. Therefore it involves the 
application of a drug to the skin to treat systemic disease and is aimed at achieving 
systemically active levels of the drug. They are occluded applications with 
compositions relatively invariant during use. They are applied on a predetermined 
surface area with a precise dose. However, drug levels in local tissue are related to 
product efficacy and the levels of drug in the blood are unavoidable which lead to 
systemic toxicity (Flynn, 1993). 
 
Percutaneous drug delivery systems have several advantages, compared to other routes 
of administration. There are no gastrointestinal irritation and no hepatic first-pass 
effect. The administration does not require needles or professional supervision and the 
treatment can be terminated immediately upon improvement of the disease. Therefore, 
these delivery systems increase patient acceptance and compliance. Transdermal 
delivery systems provide a steady maintenance of blood level over a predictable period 
of time. Compared with other dosage forms, TDDS may not be cost effective. 
However, some limitations of these delivery systems, such as cosmetic appearance, 
smell and size have to be improved as they can affect patient acceptance. The size of 
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the system will be dependent on the amount of drug released from the system and 
permeated through the skin as well as the blood level needed to elicit the desired 
pharmacological effect. If the drug is inherently skin sensitizing or irritant, skin 
irritation and sensitization may be unavoidable. Some people with very active daily life 
style or those having psychological factors such as fright and aggression may not be 
able to get a system to adhere to their skin because of excessive sweating or oiliness. 
Moreover, the usage of topical and regional delivery systems is limited to treat dermal 
disorders, with the skin as the target organ. 
 
The dosage forms for percutaneous delivery of drugs include powders, solutions, 
lotions, creams, pastes, gels, ointments, plasters and patches. Gels, plasters and patches 
are more attractive as percutaneous delivery systems. Gels are semisolid or solid 
systems consisting of a three-dimensional cross-linked polymer networks in an 
aqueous or non-aqueous liquid vehicle. Depending on the nature of interaction 
between adjacent polymer chains, gels may be categorized as chemical and physical 
systems (LaPorte, 1997). The networks of chemical gels are held together by 
covalently cross-linked polymer chains. Conversely, physical gels are composed of 
polymer chains in which interaction between adjacent polymer chains are facilitated by 
secondary molecular forces (e.g., van der Waal’s bonds and hydrogen bonding) 
(Kavanagh and Ross-Murphy, 1998). Gels can be fabricated in the form of plasters by 
spreading on a backing material. Plasters are applied to the skin to provide prolonged 





3. Considerations in the development of plasters for drug delivery 
The ideal plaster for therapeutic percutaneous drug delivery should be strong and 
flexible in nature and has a smooth and soft surface for ease of contact with the skin 
surface. It should also have strong bioadhesive properties for prolonged retention on 
the skin to allow adequate drug release and penetration through the skin to achieve 
therapeutic effect. The amount of drug at the target site should commensurate with the 
clinical requirements. The plaster should be able to be removed easily without leaving 
any residue of drug or other ingredients on the skin upon termination of the treatment. 
The plaster should not cause any irritation and harmful effect to the skin. The drug 
should be stable in the formulation during storage. The drug candidate for 
percutaneous drug delivery should possess suitable chemical properties, such as low 
dose, low polarity, low melting point, low molecular weight and lipophilicity. Other 
requirements for a drug suitable for percutaneous delivery are permeability through the 
skin, no adverse effect on the adhesiveness of the plaster such as skin irritation and 
allergic reactions, favorable pharmacodynamic and pharmacokinetic properties, 
relatively broad therapeutic window, low skin metabolism and consistent tissue drug 
level for continuous administration (Flynn and Stewart, 1988). 
 
C. Characterization of plasters  
1. Rheological properties of gels 
The clinical and non-clinical performances of polymeric gels are dependent on their 
mechanical/rheological properties. Therefore, the study of the rheological behavior of 
polymeric gels is necessary to ascertain their quality and therapeutic efficacy. 
Rheology is the study of the deformation (strain) of materials under stress applied. If 
the material regains its original shape and position when the stress is removed, it is 
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called elastic. If the material fails to do so, it is said to have flowed and is described as 
viscous. As a simplification, solids are elastic and liquids are viscous. A gel shows 
both elastic and viscous properties and is viscoelastic. Rheometry is an experimental 
method to quantify viscoelastic behavior of a gel. The most commonly used methods 
to study the mechanical and rheological properties of gel systems are flow rheometry, 
oscillatory rheometry and creep analysis. In an oscillation rheometry, the material is 
subject to a sinusoidal stress. The rheological behavior is characterized by the dynamic 
moduli G′ and G″ as a function of frequency, where G′ is the storage (elastic) modulus 
and G″ the loss (viscous) modulus. The storage modulus is a measure of the energy 
stored and recovered per cycle of deformation, reflecting the solid-like component of 
viscoelastic behavior of the material. The loss modulus is a measure of the energy lost 
per cycle, reflecting the liquid-like component (Ferry, 1980). The loss tangent, tan δ, 
calculated from the ratio of viscous and elastic moduli, provides a comparative 
contribution of elastic and viscous components to the gel system. 
 
2. The bioadhesive properties of plasters 
Bioadhesion is defined as a state in which two bodies, one or both of them of 
biological nature, are held together for an extended period of time by interfacial forces 
(Solomonidou et al., 2001). Satisfactory bioadhesion is essential for the successful 
application of a bioadhesive drug delivery system. It refers to the strength of 
attachment of the dosage form to the biological tissue. Polymers of varying structures 
have been shown to exhibit bioadhesive properties. It is generally accepted that 
polymers with strong anionic charges and a number of carboxyl or hydroxyl groups 
have good binding potential. A bioadhesive polymer should have sufficient chain 
flexibility to allow interpenetration into the biological substrate, favorable surface 
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energy properties to facilitate spreading over the biological surface, and a sufficient 
macromolecular size to produce an interpenetrating layer and entanglements. 
Polyacrylic acid polymers have been reported to possess good bioadhesive properties 
(Smart et al., 1984; Park and Robinson, 1984; Peppas and Buri, 1985). 
 
Several techniques for in vitro determination of bioadhesion have been reported, which 
include tensile testing (Park and Robinson, 1985), shear stress testing (Smart et al., 
1984), adhesion weight method (Smart and Kellaway, 1984), fluorescent probe method 
(Park and Robinson, 1984), flow channel techniques (Mikos and Peppas, 1986) and 
texture analysis (Wong et al., 1999). The measurement of forces required to detach a 
bioadhesive dosage form from a biological substrate using a tensile tester is the most 
direct way to quantify bioadhesive performance. The adhesion of plaster onto the skin 
surface can be evaluated by applying the plaster on the skin and estimating the 








Table 1. Assessment of adhesion of plaster by visual analogue scoring 
Adhesion score Description 
0 90% adhered (essentially no lifting off the skin) 
1 75% to <90% adhered (only some edges lifting off the skin) 
2 50% to <75% adhered (less than half of the system lifting off the 
skin) 
3 <50% adhered but not detached (more than half the system 
lifting off the skin without falling off) 
4 patch detached (patch completely lifting off the skin) 
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D. In vitro drug release and skin permeation studies 
In vitro techniques are simple, reliable, reproducible and relevant methods to assess 
release of drug from a dermatological product and permeation through the skin. A 
major advantage of in vitro techniques is that they allow for measurement of 
permeation through human skin of chemicals too toxic to test ethically in human 
subjects. Therefore, it is widely used in the assessment of percutaneous absorption of 
potentially toxic chemicals. Permeation rates and skin metabolism can be measured 
more accurately in an in vitro system because sampling is performed directly beneath 
the barrier layer (Aungst et al., 1986). Skin metabolism can be studied in viable skin 
without interference from systemic metabolic processes. Finally, permeation 
measurements are much more easily obtained from diffusion cells than from analysis 
of biological specimens from clinical studies. The accuracy of in vitro measurements 
depends on the use of proper methodology. 
 
1.  Drug release and permeation studies using vertical Franz diffusion cell  
Although many different diffusion cells have been used for permeation studies, there 
are only two basic cell types: one-chambered cell and two-chambered cell. The two-
chambered cell has two chambers of equal volume (often from 2 to 10 ml) that are 
separated by the skin membrane. The one-chambered cell has a chamber beneath the 
skin but is open to the environment above the skin. The two-chambered cell is useful 
for studying mechanisms of drug diffusion through the skin and also applicable to the 
measurement of permeation from drug delivery devices that release drug at an infinite 
dose and produce a steady-state rate of delivery. The one-chambered cell is useful for 
the study of permeation of chemicals through the skin and determination of steady-
state absorption kinetics. Finite-dose techniques and the design of a static diffusion cell 
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were described by Franz (1975). A flow-through cell system (Bronaugh and Stewart, 
1985) was introduced to automate sample collection from a one-chambered cell. It also 
facilitates the maintenance of skin viability since the physiological receptor fluid is 
continually replaced.  
 
An appropriate type of skin or membrane is used for evaluation of in vitro 
percutaneous penetration. There are two types of skin used in the diffusion cell 
technique, namely human skin and animal skin. Different part of the skin can be used, 
such as full-thickness skin, epidermis and stratum corneum. Female abdomen is the 
standard site for skin removal to minimize the variability in the results due to 
differences in permeability properties between different anatomical sites. Testing has 
to be repeated with skin from different donors to reduce the variation between 
individuals in skin permeability. Since animal skin is more readily available than 
human skin, it is possible to standardize the skin slice regarding anatomic site, age and 
sex of animal. However, most animals have furry skin and the thickness of the stratum 
corneum is often thinner than that of human skin. Therefore, the results obtained from 
in vitro animal skin study may not represent the in vitro human skin study. It was 
reported that pig skin has a close physiological similarity to human skin and is mostly 
recommended because of its availability (Sartorelli et al., 2000). In addition, hairless 
guinea pigs are also recommended to assess relative permeability and to compare in 
vitro and in vivo results. 
 
The full-thickness skin is the skin with the subcutaneous fat removed. The stratum 
corneum controls the rate of penetration for most compounds. After passing the 
stratum corneum, hydrophilic compounds will pass through the hydrophilic dermis 
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while lipophilic substances will be retained (at least partly) in the dermis. Therefore, 
full-thickness skin is not suitable for investigation of percutaneous penetration of 
lipophilic compounds (Sartorelli et al., 2000). However, for lipophilic drugs, an 
estimation of skin absorption can be achieved by measuring the content of the test 
substance in the skin (besides the content in the receptor fluid and surface wash). 
Isolated epidermis could be prepared by different heat separation technique using a 
water bath or microwave oven. The advantage of using isolated epidermis is that the 
penetration of both lipophilic and hydrophilic compounds can be investigated. The 
disadvantage is that the separation procedure may disturb the permeation properties of 
the skin. Dermatomed skin is a skin slice (200−400 µm) cut from the full-thickness 
skin using a dermatome. The dermatomed layer obtained includes the epidermis and 
some dermal tissue. Instead of isolated epidermis, dermatomed skin can be used to 
investigate the penetration of lipophilic and hydrophilic compounds. The cutting may 
disturb the permeation properties and it is important to ensure that the skin slice is free 
of dermis. Stratum corneum (SC) is prepared by incubating the human epidermal 
membranes with SC side upwards in 0.5% (w/v) sodium bicarbonate solution 
containing 0.1% (w/v) trypsin, at 37±1°C for 3 h. The SC is then removed, thoroughly 
washed and dried in a vacuum desiccator. After 24 h, the SC is dipped in acetone 
solution for 20 s to remove sebaceous lipids and dried again (Kligman and 
Christophers, 1963 and Kumar et al., 1989). 
 
The selection of the receptor fluid is important to create in vitro conditions that can 
adequately simulate the in vivo situation. The normal saline or an isotonic buffer 
solution could be used for measuring the absorption of water-soluble compounds. 
Some chemicals are metabolized significantly during the percutaneous absorption 
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process (Kao et al., 1984). The viability of skin can be maintained for 24 h in a flow-
through diffusion cell using a physiological buffer as the receptor fluid (Collier et al., 
1989). Drugs with water solubility of less than approximately 10 mg/l would present a 
potential problem in a diffusion cell with a standard aqueous receptor fluid (Bronaugh 
and Stewart, 1985). Thus, nonionic surfactants or non-aqueous solvents like ethanol, 
propylene glycol and polyethylene glycol 400 may be incorporated into the aqueous 
receptor fluids to increase the drug solubility in the receptor medium. The most 
effective receptor fluid that could be used without apparent damage to the skin was 
found to be the nonionic surfactant, polyethylene glycol 20 oleyl ether (Williams, 
1991). The concentration of the drug that accumulates in the receptor fluid is measured 
in the permeation study. This is commonly expressed as the cumulative amount of 
drug in the receptor fluid. When the rate of penetration through the skin reaches a 
pseudo steady-state, the flux of the drug through the skin can be obtained from the 
slope of the linear portion of the curve of the cumulative amount of drug in the 
receptor versus time.  
 
Based on acceptable in vitro/in vivo correlations, in vitro method is used as a predictor 
of in vivo performance. In in vitro drug release study, the vertical Franz diffusion cell 
system is used to assess the drug release characteristics from topical formulations 
through a commercially available mixed cellulose/cellulose nitrate synthetic 
membrane. Application of a synthetic membrane avoids certain experimental issues 
associated with the use of excised tissue but it also reduces meaningful extrapolation to 
an in vivo setting. Aliquot samples from the aqueous receptor phase can be analyzed 
for drug content by high performance liquid chromatography (HPLC) or other 
analytical methods. A plot of the amount of drug released per unit area (µg/cm2) 
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against square root of time may yield a straight line, the slope of which represents the 
release rate, also defined as the steady-state flux. This release rate is formulation-
specific and can be used to monitor batch-to-batch uniformity (Shah et al., 1992 and 
1993). The difference in slope between two batches of the same formulation or 
between two formulations relates to differences in their relative ability to release the 
drug across the synthetic membrane under the chosen experimental conditions. The 
release rate of the drug from a topical formulation largely depends on manufacturing 
variables, which influence the quality of the preparation (Shah et al., 1992). For these 
reasons, in vitro release studies using a synthetic membrane can be employed as a 
quality control measure to assess batch-to-batch uniformity. 
 
2. Guidelines for in vitro percutaneous studies to establish release and 
permeation rates of drug products (FDA and AAPS, 1987) 
Human skin should be used in the form of dermatomed sections or epidermal sections. 
In comparative studies, skin samples from the same body site should be utilized. If the 
stored skin is utilized, the conditions of harvesting and storage should be described. 
The effect of storage also should be ascertained. If volatility of the receptor medium is 
a problem, a quantitative accounting of cell design must be made. The receptor 
medium should provide an effective sink for the penetrant. In most studies, an isotonic 
solution buffered to pH 7.4 is a suitable and preferred receptor fluid. With 
hydrophobic compounds, studies should be done either by: (1) using a lipophilic 
receptor fluid that has no effect on the skin membrane or (2) using an isotonic solution 
containing an appropriate concentration of solubilizer for the hydrophobic compound. 
The surface temperature of the skin should be maintained at 32°C. The lag times and 
steady state fluxes should be set for kinetic analysis. Whenever possible the drug 
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content in both the tissue and receptor at the end of the experiment should be noted 
and the total mass balance, which includes measurement of the residual drug in the 
skin, should be determined. The maximum rate and the time to achieve the maximum 
rate can be determined and compared across different formulations. The apparent 
steady-state flux (slope) should be reported (Sartorelli et al., 2000). 
 
E. Stability testing  
When a new drug product is being formulated, it is desirable to determine the stability 
of the drug entity in the drug product so that a shelf-life or expiration date may be 
assigned to the product. The chemical stability of a drug in the desired dosage form is 
of great importance since therapeutic problems may result from poor drug stability. 
The net result of drug instability is that the patient does not receive the proper dose of 
the active drug entity and therefore, the full therapeutic effect of the drug is not 
realized. Additionally, drug decomposition may yield toxic by-products, which 
endanger the patient. The shelf-life is the length of time required for the product 
potency to be reduced to some percentage of its original value. For most products, this 
is the T90 or time at which the product retains 90% of its original potency. 
 
Stability of a product is the time interval specified by the manufacturer within which 
the characteristics of the product remain. The change of these characteristics as the 
product ages is usually called degradation. The degradation rate can be influenced by 
environmental variables such as temperature, humidity, oxygen and light. The 
formulation variables also have effects on the stability of the drug in the product. 
Products degrade faster when they are subjected to elevated temperature and humidity 
conditions, which have been used in stability testing for assessment of the shelf-life of 
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products. Usually two types of stability testing are used in practice, i.e., long-term 
stability testing and accelerated stability testing. In the long-term stability testing, 
products are stored in normal storage conditions and monitored for a period of time. 
Whereas in the accelerated stability testing, products are subjected to elevated stress 
conditions and the characteristics of the products are monitored for a period of time. 
The stability of the product at normal storage conditions is predicted from the 
degradation rates at the stressed conditions. This accelerated stability testing is 
designed to increase the degradation rate of the drug product to obtain information 
more quickly, allowing for rapid screening for stable and safe formulations. The 
current International Conference on Harmonization (ICH) guidelines recommend long-
term stability testing at 25°C/60% RH and accelerated stability testing at 40°C/75% 
RH, or if significant change has taken place at this condition, then 30°C/60% RH can 
be used as an accelerated condition. Visual inspection of changes in the physical form 
is performed and the drug and its degradation products are assayed using appropriate 
analytical methods such as HPLC technique. 
 
F. Skin irritation studies 
Skin irritation is identified as a non-immunologic local inflammatory reaction, 
characterized by erythema, edema or corrosion, following single or repeated 
application of a chemical substance to the cutaneous site. The conditions of exposure 
influencing the clinical response to chemical irritants may be divided as follows: (1) 
extrinsic factors, which influence the ability of a chemical substance to penetrate the 
skin barrier and produce an inflammatory reaction, and (2) intrinsic (constitutional) 
factors, which influence an individual’s capacity to react with an inflammatory 
response. 
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Irritation testing is conducted for several reasons. A single contact with some 
chemicals may result in acute inflammation and in some cases skin necrosis at the 
application site (Wilhelm and Maibach, 1990). Necrosis induced by chemicals is called 
corrosive. Animal tests mandated by regulatory agencies are routinely used to screen 
materials for their capability to produce acute irritation and corrosion. Chemicals that 
do not produce acute irritation from a single application may produce inflammation 
following repeated application to the skin, which is often described as cumulative 
irritation. Cumulative irritation is most often evaluated in humans. The tests for 
predicting skin irritation include conventional patch test, cumulative irritation test, 
chamber scarification test, soap chamber test and immersion technique. 
 
Patch testing is a well-established method for risk assessment and is frequently used to 
determine the irritation potential of topical agents. It involves application of test 
material under occlusive conditions and irritation is observed visually and assessed 
according to a visual analogue score (VAS) (Vowels et al., 1995). The Hill Top 
Research Inc. has developed a patch testing system using the Hill Top chamber, which 
incorporates a 0.2 ml of test sample. The test sites are examined in standard lighting 
conditions and the assessment of skin irritation is made only after application of the 
patch according to the visual scoring system (Table 2). This system has been identified 
as a preferred patch testing system on the basis of a combination of test sensitivity, test 
material volume and commercial availability. 
 
Many advanced bioengineering devices have been used to measure skin irritation. 
Laser Doppler velocimetry has attracted great interest in skin irritation study. Laser 
Doppler velocimetry is an optical technique for estimation of microcirculation, based 
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on the Doppler principle. When the laser beam from a 632-nm helium-neon laser 
source is directed toward the tissue, reflection, transmission, absorption and scattering 
occur. Laser light backscattered from moving particles, such as red cells, is shifted in 
frequency according to the Doppler principle, while radiation backscattered from non-
moving structures remains at the same frequency. Thus, increased skin blood flow, 
which has been shown to be related to skin irritation, can be measured. Recently, Laser 
Doppler perfusion imager (LDPI) for two-dimensional mapping of blood flow in 
exposed tissue was developed (Wardell et al., 1993). It is based on similar principles 
as laser Doppler velocimetry but makes it possible for quick assessment of superficial 
blood perfusion and eliminates the unavoidable skin touch of the conventional flow 
meter that may affect the measurement. It is a useful objective tool complementing 
visual assessment of skin erythema and has been used to study in vivo irritation. 
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Table 2. Visual scoring system for skin irritation (Mills et al., 1998) 
Score Irritation 
I Dermal response 
0 No evidence of irritation 
1 Minimal erythema, barely perceptible 
2 Definite erythema, readily visible; minimal edema or minimal papular 
response 
3 Erythema, edema 
4 Definite edema 
5 Erythema, edema, and papules 
6 Vesicular eruption 
7 Strong erosion spreading beyond test site 
  
II Other effects: 
A Slight glazed appearance 
B Marked glazing 
C Glazing with peeling and cracking 
D Glazing with fissures 
E Film of dried serous exudates covering all or part of the patch site 







A. Studies on therapeutic action and adverse effects of aspirin 
1. New indications of oral aspirin 
Apart from its common usage as an analgesic and anti-inflammatory drug, several 
studies have proven that aspirin can be used in antiplatelet therapy. Aspirin in doses of 
50, 100, 250, and 1000 mg daily suppressed thromboxane formation and significantly 
inhibited platelet function (Martindale, 1996). A number of clinical trials have been 
done with the use of aspirin in both primary and secondary prevention of myocardial 
infarction and stroke (Antiplatelet Trialists’ Collaboration, 1994; Hennekens, 1997). 
Experimental studies in animals and observational studies in humans indicated that 
regular use of aspirin might decrease the risk of colorectal adenomas, which are the 
precursors to most colorectal cancers. These findings were further proven by 
conducting a randomized, double-blind trial on a total number of 517 patients. The 
results from the studies showed that one or more adenomas were found in 17% of 
patients in the aspirin group and 27% of patients in the placebo group (p<0.05). It was 
concluded that daily use of aspirin was associated with a significant reduction in the 
incidence of colorectal adenomas in patients with previous colorectal cancer (Sandler 
et al., 2003). 
 
2. New indications of topical aspirin 
The afferent C-fibres subserving itch of cutaneous origin respond to histamine, 
acetylcholine and other pruritogens except mechanical stimuli. Therefore, H1-
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antihistamines are effective in treatment of insect bite reactions and most forms of 
urticaria. However, itch in systemic disease and in most dermatoses do not respond to 
low-sedative H1-antihistamines (Twycross et al., 2003). Although it has been reported 
that oral aspirin does not relieve itch (Daly and Shuster, 1986) and it can increase 
histamine induced itch (Hagermark, 1973), many studies have found that topical 
application of aspirin can be used for treatment of localized itch and pain. Aspirin is an 
inhibitor of cyclo-oxygenase enzyme which results in the inhibition of the biosynthesis 
of prostaglandins. Prostaglandins cause hyperalgesia by sensitizing the small nerve 
fiber endings to various mediators. These small nerve fibers transmit pain and itch 
mainly by C fibers. Therefore, prostaglandins play an important role in pain and itch 
(Lovell et al., 1976). Aspirin inhibits the effect of prostaglandins on these nerve 
endings (Cashman and McAnulty, 1991 and McCormack and Brune, 1991), and thus, 
topical application of aspirin can be used for treatment of localized itch and pain. In a 
single blind study of sixteen volunteers, topical application of aspirin/dichloromethane 
solution significantly reduced the duration and magnitude of histamine induced itch 
(p<0.05) (Yosipovitch et al., 1997). However, in another study, topical aspirin reduced 
skin irritation induced by sodium lauryl sulphate but did not reduce histamine induced 
itch in the model used (Thomsen et al., 2001).A clinical double-blind crossover 
placebo trial on 29 patients with lichen simplex chronicus of at least 3 months duration 
showed that LSC responded well to topical aspirin/dichloromethane solution. 
Therefore, this treatment was suggested to be a practical, safe and efficient treatment 
for lichen simplex chronicus (Yosipovitch et al., 2001). A new topical treatment for 
acute herpetic neuralgia and post herpetic neuralgia with aspirin/diethyl ether mixture 
was proven to be highly efficient treatment for both diseases from the results of an 
open-label study and a double-blind controlled clinical trial (De Benedittis et al., 
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1992). Short-Form McGill Pain Questionnaire was used to study the pain patterns and 
relationships in 42 patients with herpes zoster and post herpetic neuralgia before and 
after topical application of aspirin in chloroform. All patients from this study reported 
that pain decreased promptly after treatment, with maximum relief at 20 to 30 min and 
lasting 2 to 4 h (King, 1993). The effect of oral aspirin has been compared with topical 
aspirin/chloroform solution in patients with acute herpetic neuralgia (King, 1988). 
Topical aspirin provided significantly higher pain relief than oral aspirin in all the 
patients. Three studies have reported that topical aspirin in diethyl ether provided good 
to excellent pain relief, whereas oral aspirin provided poor pain relief. Kassirer and 
King (1988) reported that three patients with post herpetic neuralgia were treated 
effectively with aspirin dissolved in a moisturizer (Vaseline Intensive Care Lotion). 
This study was further studied by Balakrishnan et al. (2001) to prove that topical 
aspirin in moisturizer was clearly superior to oral aspirin in relieving the pain of AHN. 
Compared to oral administration, higher levels of aspirin in skin but negligible blood 
levels were observed in topical administration. It was also reported that the aspirin 
concentration in the skin was much higher than that in the blood after topical 
application (Bareggi et al., 1998). 
 
3. Adverse effects of oral aspirin 
There are many studies reporting side effects of oral administration of aspirin. 787 
reports of adverse reactions to aspirin were sent to the committee on safety of 
medicines. These included 95 reports of blood disorders and 53 reports of analgesic 
nephropathy associated with the use of preparations containing aspirin, phenacetin and 
codeine. Others adverse effects of aspirin reported were aplastic anaemia, haemolytic 
anaemia, thrombocytopenia, hyperglycaemia and glycosuria, deafness, exacerbated 
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anginal attacks, hepatotoxicity in patients with rheumatoid arthritis, systemic lupus 
erythematosus or similar disorders, toxic epidermal necrolysis, and Reye’s syndrome 
(Martindale, 1996). A report from The Dutch TIA Trial Study group, 1991 showed that 
aspirin with dose as low as 30 and 75 mg/day caused serious gastrointestinal bleeding. 
In patients with peptic ulcer and related diseases and those on warfarin, aspirin is 
contraindicated because of its gastrointestinal toxicity and aggravation of 
gastrointestinal bleeding (Shorr et al., 1993 and Turpie et al., 1993). It was proven that 
inhibition of gut cyclooxygenase enzyme by aspirin is the underlying mechanism of 
gastrointestinal toxicity (Walt, 1992 and Masferrer et al., 1993) and gastrointestinal 
bleeding was aggravated because of the gastrointestinal tract and platelets share a 
common isoform of the cyclooxygenase enzyme (Smith, 1992). 
 
According to the above reports on side effects of oral aspirin, it is unsafe to use oral 
aspirin for a prolonged period of time. Therefore, a safer route of administration of 
aspirin should be considered. Topical administration has more advantages than oral 
administration, not only in the way of less side effects but also greater therapeutic 
effect. Moreover, aspirin has physical and chemical properties that are favorable for 
percutaneous absorption, i.e. weak acid with a pKa value of 3.6, low melting point of 
143°C, low molecular weight of 180.2 and lipophilicity (British Pharmacopoeia 2000). 
Aspirin elicits its therapeutic activity with relatively low therapeutic dose of 30 mg/day 
(Patrignani et al., 1982) and is well tolerated by the skin. It was reported that 
transdermal administration of sodium salicylate, aspirin, and other non steroidal anti-
inflammatory drugs by iontophoresis has been widely used in the treatment of 
musculoskeletal illnesses (Lark and Gangarosa, 1990; Saggini et al., 1996; Demirtas 
and Oner, 1998; Rosenstein, 1999). However, one case of adverse reactions from 
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transdermal administration of lysine acetylsalicylate by anodic iontophoresis, such as 
generalized cutaneous eruption, with small, nonconfluent erythematous-pomphoid 
lesions and pruritus, lip angioedema, nasal obstruction, and a sense of constriction in 
the chest, was reported (Macchia et al., 2002). Therefore, the formulation of a safe and 
stable topical aspirin should be studied to achieve the effective therapeutic usage. 
 
B. Formulation of percutaneous drug delivery systems 
A liposome-gel formulation containing 1% (w/w) hydrocortisone was prepared to 
study the targeted and sustained delivery of hydrocortisone to normal and stratum 
corneum-removed skin without enhanced skin absorption (Kim et al., 1997). The study 
showed that percutaneous absorption of hydrocortisone across the stratum corneum-
removed skin was significantly faster than that across the normal skin, suggesting that 
the SC behaved as a penetration barrier to the liposome-bound drug. It was found that 
the liposome gel reduced the skin absorption of hydrocortisone, compared with the 
conventional ointment formulation. The amount of hydrocortisone absorbed by the 
SC-removed skin from the liposome gel after 8 h was less than one-third of that from 
the conventional ointment. In addition, higher and sustained skin concentrations of 
hydrocortisone were achieved for the liposome-gel as compared to the ointment. After 
4 h, the plasma concentration of hydrocortisone obtained from the liposome-gel was 
only one-fourth of that from the ointment (p<0.01). It was assumed that interaction of 
hydrocortisone with phosphatidylcholine, a component of the liposomes and skin, 
might retard the diffusion of the drug in the skin. However, the short retention time of 
the gel formulation prevented sufficient delivery of drug for therapeutic activity. Davis 
et al. (1997) patented supersaturated topical compositions of two miscible non-
aqueous and non-volatile solvents for topical application. A composition of the 
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invention consisted of two distinct phases, which were mixed prior to the application 
on the skin surface. Although it was suitable for delivery of water-sensitive drugs, it 
was not easy for patient to prepare as a device and it was not bioadhesive to stick on 
the body surface well. Murdock et al. (2002) invented a non-occlusive, bioadhesive 
topical systems for transdermal administration of an amine compound to relieve pain. 
The topical systems were formulated in creams or gels form comprising active 
substance dispersed in solvent. Therefore, crystallization of drug by vaporization of 
solvent and degradation of drug upon exposure to the air were not avoided. Another 
study reported that a hydroalcoholic gel formulation with hydroxypropylcellulose was 
more suitable for piroxicam than an oil-in-water cream formulation (Rafiee-Tehrani 
and Mehramizi, 2000). This study proved that an effective amount of drug was 
released from the aqueous gel formulation. However, it was not suitable for water 
sensitive drugs like aspirin and morphine. 
 
The anti-thrombotic action of aspirin on 19 healthy, male and female volunteers was 
examined by using two aspirin patch systems without (type A) and with (type B) 
limonene as a permeation enhancer (McAdam et al., 1995). Both type A and type B 
patches had the same surface area of 50 cm2. The amount of aspirin was 84 mg in type 
A patch and 120 mg in type B patch. Daily application of two type A patches (total 
surface area of 100 cm2 and total aspirin of 168 mg) for 14 days showed that 85% 
reduction in serum thromboxane B2 (TXB2) in six male subjects and 32% reduction in 
serum TXB2 in four female subjects on day 14. Analysis of the residual drug in the 
patch showed that each patch delivered 18±3 mg of aspirin on day 1 and 17±4 mg of 
aspirin on day 14, with no difference between males and females. Daily application of 
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a single patch B for 21 days resulted in 60% suppression of serum TXB2 on day 14 and 
84% suppression on day 21 in nine male subjects. The results of analysis of the applied 
patches showed that patch B delivered 33±3 mg of aspirin daily. It was reported that 
no plasma aspirin was detected, whereas plasma salicylate was 157±38 ng/ml and 
133±20 ng/ml on day 14 with patch A and patch B, respectively. Hydrolysis of aspirin 
to the inactive product, salicylic acid, was reported in three subjects. All volunteers 
exhibited mild and self-limiting skin reactions characterized by varying degrees of 
erythema and pruritus, more likely on the site of repeated application. Therefore, these 
patches are not safe for clinical use although they are therapeutically effective. 
 
C. Evaluation of physical properties of plasters 
1. Rheological properties of gels 
Polymeric gels have been used as platforms for drug delivery, primarily as a result of 
the wide range of physicochemical properties offered by such systems (Jones et al., 
1996 and 1997). Manipulations of the type and concentration of polymer used, the 
state of the polymer, the formation of gel networks and pH of the formulation are 
strategies that may be successfully used to engineer a defined product performance 
(Woolfson et al., 2001). As a result, several studies have examined the mechanical and 
rheological properties of gel systems using traditional rheological methods, e.g., flow 
rheometry, oscillatory rheometry and creep analysis. The rheological properties of 
poly(acrylic acid) gels have been characterized by dielectric spectroscopy and 
oscillatory rheometry in several studies (Barry, 1974; Craig et al., 1994). The 
rheological properties of cellulose ethers and of polymer gel networks have been 
described (Doelker, 1987 and Jones et al., 1997, 1998). Several studies on rheological 
(viscoelastic properties) and textural characteristics (hardness, compressibility, 
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adhesiveness and cohesiveness) of bioadhesive, semi-solid, polymeric systems 
containing active substances (drugs) by textural analysis and flow rheometry were 
reported by Jones et al. (1996, 1997, 1998, 2002, 2003). They used oscillatory 
rheometry and texture analyzer to examine the mechanical properties of bioadhesive 
polymeric gel for topical drug delivery. The relationship of polymer concentration and 
viscoelastic/mechanical properties of gel was reported. In oscillatory analysis, higher 
polymer concentrations increased the storage modulus (G′), the loss modulus (G″) and 
the dynamic viscosity (η′), yet decreased the loss tangent (tan δ). The relationships 
between G′ or G″ and frequency were observed to level off at higher frequencies, 
which is indicative of polymer chain entanglement and network formation. Increased 
viscosity of formulation product led to increased hardness, compressibility and work of 
syringeability of the formulation. Another study reported the viscoelastic properties of 
polymeric systems in a mixture of pharmaceutical solvents. The addition of water to 
nonaqueous Carbopol 934P solution caused the transformation of the low viscosity 
solution to a gel with significant elastic behavior, due to physical interaction and 
entanglement of the polymer segments with solvents such as propylene glycol, 
glycerol and water (Chu et al., 1992). 
 
2. Bioadhesive properties  
Bioadhesive polymers, as components of drug delivery systems, enable adhesion of the 
systems to skin surfaces and thus may facilitate drug delivery to defined sites. 
Presently, there is no universal test method for bioadhesion measurement and some 
results of bioadhesion studies reported in the literature appeared to be contradictory 
(Smart et al., 1984; Jones et al., 1996; Gandhi et al., 1994; Jones et al., 1997; Chary et 
al., 1999 ; Solomonidou et al., 2001). The results were dependent on the methods used. 
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Tensile testing is a simple method to study the adhesive properties of formulations. It 
involves the determination of the detachment force required to overcome the adhesive 
bond between the formulation and a substrate. It was reported that films based on 
polyvinylpyrrolidone were generally more mucoadhesive than corresponding 
formulations based on polyvinyl alcohol. The optimal mucoadhesive polymer 
concentration range was generally found to be between 2 and 10% (w/w). Higher 
polymer concentrations did not further enhance the mucoadhesive properties, and in 
some cases even decreased mucoadhesion. Tensile testing was used to determine the 
mucoadhesive properties of three structurally similar polyacrylic acid polymers that 
differ in the extent of cross-linking, namely Carbopol 974P, Carbopol 971P and 
Noveon AA-1 (polycarbophil). The hydration time was found to affect the 
mucoadhesive performance. The adhesiveness decreased rapidly when certain levels of 
hydration were achieved. The clinical performance of topical products is directly 
related to their hardness, compressibility, adhesiveness and cohesiveness 
(Solomonidou et al., 2001). Lin et al. (1993) have described the relationship between 
the viscoelastic properties of hydroxypropylmethylcellulose gels and their clinical 
performance. Tamburic and Craig (1995) also reported the relationship between 
adhesiveness of polymeric formulations and loss tangent. Therefore, in the 
development of formulations for topical application, the consideration should be given 
to the viscoelastic properties to ensure optimization of product performance. The 
adhesion properties of formulations were also evaluated by an in vivo method that 
employed a visual scoring system. The in vivo adhesiveness of two types of glyceryl 
trinitrate transdermal patch (Epinitril: EPI-10 and ND-10) was assessed to find a 
compromise between good and lasting adhesion and easiness of removal (Santoro et 
al., 2000). A slightly partial detachment of the border of the patch or formation of 
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creases occurred in most applications of EPI-10 and ND-10. Complete detachments or 
migrations were not observed. The difference of adhesion between EPI-10 and ND-10 
was not significant. Due to inter-individual differences of the skin, a total and lasting 
adhesion in all subjects was seldom achieved. 
The clinical and non-clinical performances of the polymer gels are dependent on their 
viscoelastic and bioadhesive properties. The cross-linked and viscoelastic gel 
ascertains the stability and durability of the plaster and also increases the bioadhesion 
of the plaster. Therefore, it is useful as a percutaneous delivery system to prolong drug 
residence time at the site of application and allows an enhancement in absorption of 
the drug. 
 
D. In vitro drug release and skin permeation studies 
The diffusion cell method is the standard method for in vitro percutaneous permeation 
studies. The vertical Franz diffusion cell is most commonly used in almost all of the in 
vitro studies on percutaneous absorption of drugs. A buffer solution is normally used 
for hydrophilic compounds (Skelly et al., 1987) and solubilizing additive is used for 
lipophilic compounds (Moser et al., 2001) for the receptor compartment of the 
diffusion cell.  
 
The human skin is the best and most relevant skin model for in vitro percutaneous 
absorption studies (Sekkat and Guy, 2001). Skins of animals, such as mouse, rat, 
guinea pig, rabbit and pig, have been used as a model skin because the availability of 
human skin is limited. The pig skin most resembles the human skin in histological and 
biochemical properties (Gray and Yardley, 1975; Meyer et al., 1978; Klain et al., 
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1979). The epidermis from the pig ear skin was considered a good model for the study 
of percutaneous absorption of drugs and the effect of penetration enhancers on skin 
(Kligman and Christophers, 1963; Chambin et al., 1993; Hoeck et al., 1997; Bhatia 
and Singh, 1997; Levang et al., 1999). A few studies have proven that the permeability 
of drugs through pig skin is similar to that through human skin (Roberts and Mueller, 
1990; Dick and Scott, 1992; Pendlington et al., 1998). Other animal skin models show 
higher skin permeation rates than that of human skin models. The excised human 
breast skin showed lower penetration rate than skin from other anatomical sites 
(Harada et al., 1993). After comparing four animal skin membranes (mouse, rat, rabbit, 
pig) and human skin, Wu et al. (1997) proved that the excised human breast skin was 
the least permeable of all the skin type and it had no significant difference in 
permeation compared with pig skin.  
 
The permeation of lipophilic drugs is significantly and artificially impeded in vitro 
when the skin membrane includes a significant part of the dermis. Therefore, the 
epidermis is used for lipophilic drugs (Hawkins and Reifenrath, 1986; Kemppainen et 
al., 1991; Reifenrath et al., 1991; Tata et al., 1994). For polar drugs of high aqueous 
solubility, the stratum corneum barrier is completely rate limited; hence, stripped skin 
(skin without stratum corneum) is recommended (Scott et al., 1992). Full-thickness 
human cadaver skin was used for in vitro skin permeation study of naloxone and 
examination of the effects of various penetration enhancers on skin (Aungst et al., 
1986). The other studies using the viable skin (epidermis plus dermis) and stripped 
skin (stratum corneum removed skin) proved that percutaneous absorption of 
hydrocortisone across stripped skin was significantly faster than that across normal 
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viable skin, suggesting that stratum corneum behaves as a penetration barrier for the 
liposome gel formulation (Kim et al., 1997). 
 
Several studies have proven that different types of penetration enhancers had different 
effects on in vitro percutaneous absorption of active substances. The most commonly 
used enhancers are ethanol, propylene glycol, fatty acids, fatty alcohols, aliphatic 
esters, surfactants, sulfoxides, amides and N-methyl-2-pyrrolidone (NMP). Propylene 
glycol, ethanol and N-methyl-2-pyrrolidone increase drug solubility in the skin and 
enhance skin permeation. The stratum corneum uptake of propylene glycol led to 
higher solubility of ibuprofen in the skin (Irwin et al., 1990) and increased skin 
permeation of metronidazole (Wotton et al., 1985). Bhatia and Singh (1997) proved 
that the higher permeability of luteinizing hormone-releasing hormone (LHRH) 
through pig epidermis was observed with NMP and isopropyl myristate. However, 
Park et al. (2001) found that only fatty alcohols enhanced the skin permeation of 
captopril and no significant enhancing effect was produced by dimethyl sulfoxide, 
NMP and oleic acid. In vitro release of drug from a topical product might also be used 
to predict in vivo performance. A rank order correlation between in vitro release rate 
and in vivo blanching intensity has been observed for two brands of betamethasone 
valerate cream in healthy subjects (Shah et al., 1992). A similar rank order correlation 
has been observed for two brands of hydrocortisone cream between in vitro release 
through a synthetic membrane and drug concentration in the stratum corneum. The 
correlation with skin blanching in healthy subjects was also shown in this study (Caron 
et al., 1990) 
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E. Stability of aspirin 
Aspirin is a moisture sensitive drug that breaks down to give acetic and salicylic acids. 
The degradation of aspirin has been generally considered to be due to a hydrolytic 
reaction in the presence of water. It also decomposes in polyethylene glycol by a 
transesterification process. Therefore, its stability is often the initial concern in 
formulation development.  
 
Spancake et al. (1991) and Garrett (1957) extensively studied the hydrolysis of aspirin 
in aqueous solutions. The effect of water on the rate of degradation of aspirin was 
greater in methoxypolyethylene glycol than in polyethylene glycol. A small effect of 
added water on the degradation of aspirin in polyethylene glycol suggested that aspirin 
molecules might be entrapped in polyethylene glycol in the presence of water, 
reducing a molecular contact between water and aspirin. The greater effect of water on 
degradation of aspirin in methoxypolyethylene glycol might be due to the fact that in 
methoxypolyethylene glycol a transesterification reaction was partly blocked and when 
water was added the unreacted aspirin became available for hydrolysis. It was 
concluded that stability of aspirin might be achieved in polyhydric alcohols by 
blocking the free hydroxyl group in aspirin molecule. Citric acid tended to slow down 
the decomposition process even in the presence of added water (Whitworth et al., 
1973). Whitworth and Asker (1973) also reported that aspirin demonstrated the 
greatest stability in decaglycerol octaoleate and the lowest stability in decaglycerol 
tetraoleate at 4, 26 and 45°C. They proved that the hydroxyl value and the viscosity of 
the polyglycerol ester influenced the stability of aspirin. Excipients can have effects on 
aspirin stability under accelerated stability conditions. Cunningham and Scattergood 
(2001) examined the effect of Starch 1500, a partially pregelatinized starch, in 
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combination with microcrystalline cellulose and two hydrophilic superdisintegrants on 
the stability of aspirin tablets. Starch 1500 has a lower propensity for moisture 
absorption than either croscarmellose sodium or sodium starch glycolate. Thus, Starch 
1500 inhibited water activity within the formulation and retarding moisture interaction 
with aspirin. It was found that Starch 1500 reduced or eliminated the deleterious 
effects of other excipients in the study. 
 
Accelerated stability studies are a common approach for predicting the long-term 
stability of pharmaceutical formulations. The chemical and physical stability of 
nifedipine sustained release dosage forms prepared with Gelucire® 53/10 was 
investigated by using accelerated stability study. This study suggested that moisture-
resistant packaging was useful for the acceptable shelf-life of this type of dosage form 
(Remunan et al., 1992). Another accelerated stability study showed that the solid state 
of contraceptive steroid, Nestorone (in powder form or incorporated into silastic 
implants) did not undergo detectable degradation even under severe experimental 
conditions (Ahmed et al., 1995). Gleditsch and Waaler (2001) evaluated the shelf life 
of sodium metabisulphite stabilized morphine injections in plastic ampoules at 
temperatures ranging from 50 to 80°C. Proniuk et al. (2002) suggested that non-
aqueous solvents such as glycerin and Transcutol P should be utilized in the 
development of a topical formulation for stability of the active ingredients. Although 
many studies proved that accelerated stability studies predict the long term stability 
study for preformulation study of pharmaceutical products, Nakamura et al. (2002) 
found that accelerated stability testing failed to predict the stability of minodronic acid 
liquid formulation stored in SiO2 treated glass ampoules. It was due to the complex 
formation between the drug and aluminum ions leached from the glass of regular 
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ampoules. This complex formation was exothermic reaction and could not be observed 
at elevated temperatures. Therefore, the accelerated stability testing failed to predict 
the stability of minodronic acid injection liquid. 
 
F. Skin irritation studies 
1. Patch testing and VAS assessment of skin irritation  
Many consumer product companies developing topical medications are interested in 
assessing skin irritation before further development of the final product. Patch testing 
is frequently used to determine the irritation potential of topical agents. Mills et al. 
(1998) conducted two randomized clinical trials on 21 and 18 subjects respectively to 
assess the irritation potential of commercially available tretinoin formulations, 
compared with tretinoin formulations containing polyolprepolymer-2. The study 
employed a standard Hill Top occlusive chamber (25 mm diameter) and a visual 
scoring system for grading irritation. 
Cumulative irritation is most often evaluated in humans, however, a variety of 
exaggerated exposure tests have been employed in animals. The modifications of the 
method described by Draize et al. (1944a, 1944b) are used to evaluate primary 
irritation and corrosion in animal tests. Haeberlin (1959) reported the use of a guinea 
pig model to demonstrate heightened irritability of the skin due to irritant dermatitis to 
40% croton oil. However, this observation differed from that seen in humans, in that a 
more extensive or chronic dermatitis did not further heighten the susceptibility to 
irritation (Roper and Jones, 1985). Another study used rabbit to determine the relative 
irritancy of three cosmetic samples of known human irritancy. In this study, the visual 
estimation of irritation was based on the Uttley and van Abbe’s method (1973). 
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Allergic and toxic contact reactions in guinea pigs have been studied with the naked 
eye assessment of erythema and oedema (Anderson and Staberg, 1985). Another study 
reported that sodium lauryl sulphate induced skin irritation on guinea pigs was studied 
with naked eye assessment method (Anderson et al., 1986). Although VAS method is 
common and useful technique to assess skin irritation, it has some disadvantages such 
as inter-individual variance among examiner’s assessments and qualitative detection of 
visible skin irritation.  
2. Laser Doppler perfusion imager assessment of skin irritation 
The objective, non-invasive and quantitative assessment technique is desirable to 
complement the VAS method. This is made possible with laser Doppler perfusion 
scanning technology (Serup and Jemec, 1995). Laser Doppler velocimetry has been 
widely used to investigate vascular disorders and physiopathological changes in skin 
microcirculation. It is a continuous and non-invasive recording of microvascular tissue 
perfusion, which enables simultaneous measurement of average velocity and 
concentration of blood cells in the illuminated tissue volume. Such tissue perfusion 
measurements typically show large variations due to the high spatial resolution of this 
technique, even at adjacent sites. Therefore, it might be useful to represent perfusion as 
an image rather than as a single value recorded at one point (Issachar et al., 1998). This 
study was further studied by Sorensen et al. (1996) on two patients with reflex 
sympathetic dystrophy. The technique has been used to scan superficial blood 
perfusion in patch test reactions (Fischer and Bjarnason, 1996; Quinn et al., 1993; 
Mattsson et al., 1997; Wardell et al., 1996; Bjarnason et al., 1999; Fullerton et al., 
2001 & 2002), as well as in other applications (Harrison et al., 1993; Mayrovitz and 
Carta, 1996; Wang et al., 1997; Fullerton et al., 1995; Mannor et al., 1996). Bjarnason 
et al. (1999) supported the claim that the laser Doppler perfusion scanning technology 
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is valuable for non-invasive objective assessment of patch test reactions. Laser 
Doppler imaging was found to be an important new method for characterization and 
grading of the inflammatory response of single exposure irritant reactions (Fullerton et 
al., 2002). However, Noon et al. (1996) concluded that laser Doppler instruments, 
including the novel scanning perfusion imager, did not detect glucocorticoid-induced 
skin blanching, perhaps because it reflected venular rather than arteriolar 
vasoconstriction.  
 
The correlation between laser Doppler perfusion imaging and visual scoring of patch 
test sites was studied in subjects with experimentally induced allergic and irritant 
contact reactions. It was found that LDPI correlates with VAS in contact allergic 
reactions, but not in irritant reactions (Goon et al., 2004). 
 
G. Summary 
In summary, topical application of aspirin is an attractive mode of delivery due to its 
indications for treatment of itch and pain and its advantages of less systemic adverse 
effects on the gastrointestinal tract. Although different types of formulations for topical 
aspirin have been studied, none of them was successful due to instability and skin 
irritation of aspirin. It is important to develop a strong bioadhesive topical formulation 
to achieve a safe, stable and therapeutic topical application of aspirin. Measurement of 
viscoelastic properties of aspirin gel by rheometer, measurement of detachment force 
of aspirin plasters by tensile tester and animal adhesion test are basic methods to assess 
the physical properties and bioadhesiveness of aspirin plasters. Different types of 
bioadhesive polymers and chemical penetration enhancers play essential roles in drug 
release and skin permeation of drug. In vitro drug release study and skin permeation 
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through pig skin and human skin using vertical diffusion cells give good estimation of 
amount of drug released and permeated through skin in vivo. Accelerated stability 
testing is a convenient method to assess the shelf-life of final product in short period. 
Quantitative assessment of skin irritation using non-invasive techniques such as LDPI 





AIMS AND OBJECTIVES 
 
The aim of this study is to develop a safe, stable, bioadhesive and non-aqueous aspirin 
gel plaster for the treatment of localized pain and itch. 
 
Hence, the objectives of this study were: 
1. To formulate a non-aqueous, bioadhesive aspirin gel plaster. 
2. To study physical properties of the polymer-drug matrix gels using rheometer and 
tensile tester. 
3. To study bioadhesion of the plaster in pigs. 
4. To study in vitro drug release through synthetic membranes using Franz diffusion 
cells. 
5. To study in vitro skin permeation using pig and human skins. 
6. To study stability of aspirin plaster using accelerated stability testing. 
7. To study in vivo skin irritation of the plaster using visual analogue scoring method 







Copolymer of N-vinylacetamide and sodium acrylate (PNVA, VIAC GE-167, Lot No 
820505) was supplied by SHOWA DENKO K.K (Japan). Aluminum chloride 
anhydrous (AlCl3) was obtained from Fluka Chemika (Germany). Aspirin (purity 
99.5% to 100%, BP grade) and salicylic acid (purity 99%, BP grade) were purchased 
from Sigma-Aldrich Pte, Ltd, Singapore. N-methyl-2-pyrrolidinone (Pharmasolve®, 
NMP) was supplied by International Specialty Product (ISP, USA). Propylene glycol 
(PG) was obtained from BDH Laboratory (UK). Absolute alcohol (ethanol) and 
methanol (analytical grade) were procured from Fisher Scientific (UK). Acetonitrile 
(HPLC grade) was obtained from EM Sciences, MERCK (Germany). Potassium 
dihydrogenphosphate salt was obtained from Sigma Chemical (USA).  
 
B. Formulation of aspirin plasters 
The gel was made by using PNVA polymer as a matrix material and aluminum 
chloride as a cross-linking agent. Specific amounts of polymer and aspirin were 
completely dissolved in a mixture of NMP, PG and ethanol. The final solution was 
poured into a plastic petri dish of 85 mm diameter and allowed to stand overnight to 
remove air bubbles. The required amount of aluminum chloride in a mixture of ethanol 
and glycerin, at a weight ratio of 20 to 1, was gently added onto the above mixture on 
the following day. The final mixture in the petri dish was dried at room temperature for 
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2 days to evaporate the ethanol and then left in a desiccator for a week to avoid 
moisture. The cross-linked gel was transferred onto a non-woven cotton wool backing 
layer and protected by a plastic release liner. Three formulation variables were studied 
and optimized, including polymer concentration, polymer to cross-linking agent ratio 
and PG to NMP ratio (Table 3). The amount of aspirin-containing casting solution in 
each petri dish was about 3.4 to 4.4 g and the amount of aspirin per square centimeter 
of plaster was approximately 1.4 mg.The aspirin plasters with different amounts of 
aspirin (200, 300 and 400mg) were also formulated with polymer concentration of 9%, 
polymer to cross-linking agent ratio of 1.5:1 and PG to NMP ratio of 2:1 to assess the 
effect of aspirin itself on skin irritation. 
 
C. Measurement of rheological properties of gels 
Oscillatory rheological measurements were carried out using a rheometer 
(RheoStress® 1 Haake, Germany) with a cone-plate sensor system of diameter 35 mm 
and cone angle of 1º. Samples were applied to the lower plate and allowed to 
equilibrate to the measurement temperature of 25°C. The linear viscoelastic regions for 
the gels were determined by torque sweep studies from 0.5 to 500 Pa at a frequency of 
10 Hz. A torque value representative of the linear viscoelastic region was chosen for 
the frequency sweep analysis. The oscillatory measurements were performed over a 
frequency range of 1 to 10 Hz at a stress of 10 Pa at 25°C. Rheological parameters 
including the elastic modulus (G′), viscous modulus (G′′) and loss tangent (tan δ) were 
obtained respectively. Each datum point was the mean of at least three measurements. 
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Table 3. Compositions of polymer-drug matrix gels 
Formulation variables Amount of ingredients in polymer-drug matrix gels (g) 
 PNVA AlCl3 PG NMP Glycerin Aspirin
Polymer concentration       
5% 0.17 0.11 2.08 1.06 0.70 0.10 
7% 0.23 0.15 2.05 1.02 0.70 0.10 
9% 0.30 0.20 2.00 1.00 0.70 0.10 
11% 0.36 0.24 1.95 1.00 0.70 0.10 
13% 0.43 0.29 1.91 0.96 0.70 0.10 
PNVA to AlCl3 ratio       
2.5:1 0.29 0.12 2.00 1.00 0.70 0.10 
2:1 0.29 0.15 2.00 1.00 0.70 0.10 
1.5:1 0.30 0.20 2.00 1.00 0.70 0.10 
1:1 0.29 0.29 2.00 1.00 0.70 0.10 
1:1.5 0.29 0.45 2.00 1.00 0.70 0.10 
PG to NMP ratio       
1:2 0.30 0.2 1.00 2.00 0.70 0.10 
1:1 0.30 0.2 1.50 1.50 0.70 0.10 
2:1 0.30 0.2 2.00 1.00 0.70 0.10 
3:1 0.30 0.2 2.25 0.75 0.70 0.10 
4:1 0.30 0.2 2.4 0.60 0.70 0.10 
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D. Bioadhesion studies 
1. Tensile testing for bioadhesion 
The bioadhesive properties of the plasters were investigated by using a tensile tester 
(Shimadzu, EZ tester, Japan) in the tensile mode. The plaster was cut into strips of 
1.5×1.5 cm size. The strip for tensile testing was adhered to the lower stationary 
compression plate of the tensile tester with double-sided adhesive tapes. The model 
substrate, a silicone elastomer, which was used to simulate the skin in terms of 
bioadhesion, was mounted onto the upper plate. The upper plate with the substrate 
attached was then lowered to the surface of the plaster and allowed to remain in 
contact with the plaster for 30 s under load of 10 N. It was then raised at a speed of 100 
mm/min to detach the substrate from the plaster. The detachment forces, which 
represented the bioadhesive properties of the plasters in this study, were recorded. Six 
strips were evaluated for each plaster and the results averaged. 
 
2. Bioadhesion study in pigs 
The bioadhesive properties of the plasters in pigs were evaluated by a scoring method 
(Hill Top Research, Inc., East Brunswick, USA). Yorkshire pigs (female, 11-15 weeks 
old and 25-35 kg) were used in this study. The dorsal area of pigs, under general 
anaesthesia (intramuscular injection of Atrosite 0.07 mg/kg and Ketapex 20 mg/kg), 
was clipped free of hair one day prior to the commencement of the test. Care was taken 
to avoid abrading the skin. Each pig was housed in individual cage. Different 
formulations of aspirin plaster were applied on the dorsal area of the pigs for 8 h. An 
adhesion score was assigned according to the percentage of the plaster adhered to the 
skin (Table 1). Three determinations were made for each formulation and the results 
averaged. 
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E. Drug assay by HPLC 
Aspirin and salicylic acid were assayed by using an HPLC system (Thermo-separation 
Products USA), consisting of gradient pumps (Spectra system P4000), a vacuum 
membrane degasser (SCM1000), photo diode array detector (Spectra system SN4000) 
and autosampler (Spectra system AS3000). Separation of aspirin and salicylic acid was 
performed using a column (Hypersil BDS-C18, 4.6×100 mm, 3 µm, Agilent 
Technologies, USA) and a guard column (Hypersil ODS, 4.0×20 mm, 5 µm, Agilent 
technologies, USA) at 40°C. The mobile phase consisted of 70% v/v phosphate buffer 
(0.02 M KH2PO4 in water adjusted to pH 2.6 with 0.1 M 85% orthophosphoric acid 
solution) and 30% v/v acetonitrile. The flow rate was set at 1 ml/min. Aspirin and 
salicylic acid were detected at 230 nm. The retention times of aspirin and salicylic acid 
were 3.2 and 4.1 min respectively. 
 
Aspirin and salicylic acid solutions in mobile phase were freshly prepared before 
injection into the column. Five concentrations of aspirin and salicylic acid ranging 
from 1 to 5 µg/ml were prepared on a daily basis by dilution of the stock solutions 
(100 µg/ml) with the mobile phase, respectively. The peak area of each compound was 
plotted against the concentration to obtain the calibration curves. Accuracy and 
precision were evaluated with values obtained from analyses of five standard samples 
for intra-day and inter-day variation. Accuracy was calculated as percentage of the 
concentrations measured versus the known concentrations. Precision was determined 





F. Determination of drug content of the plasters 
Aspirin plaster was cut into square pieces of 1 cm2 size and dissolved in 5 ml of pH 7.4 
phosphate buffer for 1 h. 50 µl of aliquot was diluted with 700 µl of mobile phase and 
assayed with HPLC. The aspirin content was calculated from the total amount of 
aspirin divided by the area of plaster. The uniformity of the drug in the plaster was also 
determined by assaying the drug content from five different areas of the plaster and the 
results were averaged. 
 
G. Drug release and permeation studies 
Vertical Franz diffusion cell system (MicroettePlus system, Hanson Research, USA) 
was used in the drug release and permeation studies (Figure 3). The dosage wafer 
loaded with aspirin plaster was assembled on the synthetic membrane, a regenerated 
cellulose membrane (Spectrum Laboratories Inc, USA) with pore size of 0.45 µm. This 
dosage wafer with synthetic membrane, facing downwards, was mounted onto the 
receptor compartment. The receptor compartment was filled with 7 ml of pH 7.4 
phosphate buffer solution at 32°C which was kept stirring at 100 rpm by helix mixer 
over the course of the experiment. The area of the plaster available for drug release 
was 1.8 cm2. At predetermined time intervals over a period of 12 h, 1.5 ml of samples 
were withdrawn from the receptor compartment with replacement of an equal volume 
of fresh pH 7.4 phosphate buffer solution to maintain constant volume. The samples 
obtained were analyzed by HPLC and cumulative amounts of drug released or 
permeated were determined. All the experiments were repeated at least six times and 
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Figure 3. Diagram of (a) application of aspirin plaster into the dosage wafer and 
(b) the vertical diffusion cell used in MicroettePlus system 
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The vertical Franz diffusion cell system (MicroettePlus system, Hanson Research, 
USA) was also used for the skin permeation studies. The test procedure was similar to 
that of the drug release studies, except that the epidermis from pig abdominal skin and 
human abdominal skin were used. Six epidermis pieces were used for each formulation  
of the aspirin plaster. The pigs (Yorkshire, female, 25−35 kg, 11−15 weeks old) used 
to harvest abdominal skin were sacrificed and the skins obtained within half an hour. 
The human abdominal skin was obtained from patients undergoing liposuction 
operation (male and female, 35−65 years, Chinese). The consent of the patients was 
taken to use their disposed skin in this study. The human epidermis was removed by 
using heat separation technique. The human epidermis was taken after the whole skin 
had been soaked in water at 60°C for 2 min and rinsed with normal saline solution. It 
was then rinsed several times with distilled water until all sodium chloride was 
removed and stored at –80°C until use. Prior to use, the epidermis was hydrated by 
soaking in pH 7.4 phosphate buffer for 30 min.  
 
The aspirin plaster with polymer concentration of 9%, polymer to cross-linking agent 
ratio of 1.5:1 and PG to NMP ratio of 2:1 was used to compare the amount of aspirin 
permeated through 3 different barriers: synthetic membrane, pig skin and human skin. 
Six samples were used for each barrier. The amount of aspirin permeated through 3 
barriers was obtained as same procedure mentioned in drug release and permeation 
studies. 
 
H. Accelerated stability testing 
The aspirin plasters were stored in a climatic chamber (KBF 240WTB Binder 
Labortechnik, Germany) at an elevated temperature of 40°C and relative humidity of 
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75% for 4 weeks. Samples were then removed and assayed for aspirin and salicylic 
acid using HPLC according to the procedure described previously (Section G). 
 
I. Skin irritation studies 
The dorsal area of healthy female Yorkshire pigs (11−15 weeks old), under general 
anaesthesia (intramuscular injection of Atrosite 0.07 mg/kg and Ketapex 20 mg/kg 
body weight of pig), were clipped free of hair one day prior to the commencement of 
the test. Care was taken to avoid abrading the skin. Three determinations on three 
different pigs were made for each formulation. Each pig was housed in individual 
cage. Test plasters with different formulations were applied on dorsal area of pig with 
2.5 cm distance and placebo plasters were applied parallel to their corresponding test 
plasters. The test and placebo plasters were replaced with the new plasters of the same 
formulations on a 2-day interval basis. All test sites were covered with surgical gauze. 
The pigs were housed at room temperature 20±2°C and relative humidity of 30 to 70% 
for 14 days. On the day of measurement, the pigs were allowed to be accommodated to 
temperature and humidity of the environment in the test room (20±2°C, 30 to 70% 
R.H.) before the plasters removed. The condition of the skin at the center of 
application site was then evaluated by the visual scoring method and the cutaneous 
blood flow of the skin were measured by laser Doppler perfusion imager (Lisca 
Development AB, Sweden) on day 0 before application of the plasters and 15 minutes 
after removal of the plasters on day 2, day 4, day 6, day 8, day 12 and day 14. 3 results 
reading of VAS and LDPI of 3 pigs for each formulation were averaged and compared 
among different polymer concentrations, different polymer to cross-linking agent 
ratios, different PG to NMP ratios and also among different days of assessment by 
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using two-way ANOVA. The results were compared between placebo plasters and 
their corresponding aspirin plasters by using Student’s paired t-test. The plasters with 
aspirin concentrations of 200, 300 and 400 mg were applied for 14 days as same as 
above mentioned procedure and assessed the skin irritation with VAS and LDPI 
methods. 
 
Visual analogue scale was used to assess skin erythema with visual assessment scores 
ranging from 0 (no irritation) to 7 (strong reaction). The test sites were examined in 
standard lighting conditions and given a score by a trained independent observer who 
was unaware of the order of type of plaster applied.  
 
In LDPI testing, the test areas were assessed using a laser head aperture at a distance of 
17 cm from the center of the site of plaster application. A back ground threshold of 6.1 
V, high resolution, an amplification factor of 1 and an angle as close to 90° as possible 
between the LDPI laser beam and the center of the plaster were set. A total number of 
256 test sites (16×16 mm) were scanned. The mean flux was calculated using LDI 2.5 
software. Mean LDPI values were expressed as a percentage of voltage. Biological 
zero (LDPI values measured on normal healthy skin of dorsal area of pigs on day 0) 
was subtracted from all readings. 
 
J. Data processing and analysis 
The following steps were carried out in data processing and analysis. 
1. Before the analysis of the data, a thorough check of the experimental data was done 
to avoid any mistakes. 
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2. Throughout this study, regression equation and regression coefficient were used.  
3. Two-way ANOVA and general linear model were used to analyze the relationship 
of formulation factors, such as polymer concentration, polymer to cross-linking 
agent ratio and PG to NMP ratio, on drug release and permeation, viscoelastic 
properties, detachment force, bioadhesion scores, VAS and LDPI results. 
4. Student’s paired t-test was used to assess the differences of LDPI and VAS 
between aspirin plasters and control plasters. 
5. The Pearson’s correlation coefficients were calculated to assess the relationship 
among different formulation variables and viscoelastic properties, drug release, 
drug permeation and skin irritation. 
6. The level of statistical significance was set at < 0.05. 






A. Formulation of aspirin plasters 
Figure 4 shows the structure of the aspirin plasters. It consisted of three layers, namely, 
a backing layer, a polymer-drug matrix gel and a release liner. The backing layer and 
release liner had thickness of 0.03 and 0.13 mm, respectively. The thickness of the gel 
varied from 0.23 to 0.54 mm, depending on the formulation. Drug was dissolved 
evenly in the polymer matrix gel. The weight/area ratios of the plasters prepared from 
the same formulation demonstrated low standard deviation values, indicating good 
reproducibility in the production of aspirin plasters.  
 
The polymer concentration, polymer to cross-linking agent ratio and PG to NMP ratio 
had different effects on the physical properties of the polymer-drug matrix gels. The 
physical properties of these polymer-drug matrix gels are summarized in Table 4. All 
polymer-drug matrix gels obtained from different formulations were transparent gels. 
With increasing polymer concentration, the polymer-drug matrix gels formed became 
harder and less bioadhesive. The formulation of 5% polymer produced soft and liquid-
like polymer-drug matrix gel. When it came in contact with skin, the moderately wet 
and viscous surface left viscous gel on the site of application. The polymer-drug matrix 
gel with 7% polymer concentration was soft and semisolid. Its slightly wet and viscous 











Polymer-drug matrix gel 
 
 
Non-woven cotton wool backing layer 
Figure 4. The structure of the aspirin plasters 
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Table 4. Physical properties of polymer-drug matrix gels 
Formulation 
variables 
Texture State Type of 
Surface 
Comment 
PNVA     
5% soft liquid moderately 
wet & 
viscous 
liquid gel left on skin after 





left semisolid gel on skin after 
removal of plaster 
9% soft & 
elastic 
solid dry & 
smooth 
left no remnants on skin after 
removal of plaster 
11% firm solid dry & 
slightly 
rough 
adhere to the skin for few hours  
13% hard solid very dry & 
rough 
adhere to the skin with applied 
pressure for few hours  
PNVA to AlCl3 ratio   





left sticky gel on skin after 





semisolid gel left on skin after 
removal of plaster 
1.5:1 soft & 
elastic 
solid dry & 
smooth 
left no remnants on skin after 
removal of plaster 
1:1 firm solid dry adhere to skin for few hours 
1:1.5 hard solid very dry adhere to skin for few hours 
PG to NMP ratio    
1:2 soft solid smooth 
sticky 
left sticky gel on skin after 
removal of plaster 
1:1 soft solid slightly 
sticky 
left sticky gel on skin after 
removal of plaster 
2:1 soft & 
elastic 
solid dry & 
smooth 
left no remnants on skin after 
removal of plaster 
3:1 soft and 
viscous 
solid viscous left viscous gel on skin after 
removal of plaster 
4:1 soft and 
viscous 
solid viscous left viscous gel on skin after 
removal of plaster 
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polymer produced soft, elastic and solid-like polymer-drug matrix gel. Its smooth and 
dry surface left no residues on the skin upon removal from the site of application. 
The.polymer-drug matrix gel formulated with 11% polymer concentration was firm 
and solid which showed slightly rough and dry surface that adhered on the skin surface 
for few hours. The formulation of 13% polymer formed a hard and solid polymer-drug 
matrix gel with moderately rough and very dry surface which adhered on the skin 
surface with applied pressure for few hours. 
 
Increasing the ratio of polymer to cross-linking agent decreased the cross-linking 
density of the polymer-drug matrix gel and it led to the formation of a more sticky gel. 
With polymer to cross-linking agent ratio of 2.5:1, glue like semisolid polymer-drug 
matrix gel was formed. The surface of the gel matrix was smooth but sticky and a 
sticky gel was often left on the skin after removal of the plaster. At a ratio of 2:1, the 
semisolid polymer-drug matrix gel showed a smooth and slightly sticky surface. After 
removal, the plaster left behind semisolid gel pieces at the site of application. The 
formulation with a polymer to cross-linking agent ratio of 1.5:1 formed a soft and 
elastic solid polymer-drug matrix gel which had a smooth and dry surface. It could be 
removed from the skin without leaving behind any debris. At a ratio of 1:1, the solid 
polymer-drug matrix gel formed firm and dry surface which made plaster adhered to 
the skin for few hours. The polymer to cross-linking agent ratio of 1:1.5 gave hard 
solid polymer-drug matrix gel and formed plaster with very dry and less adhesive 
surface to skin. 
 
The PG to NMP ratio also influenced the physical properties of the gels. A solid 
polymer-drug matrix gel with smooth sticky surface was formed with PG to NMP 
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ratios of 1:2 and 1:1 and left sticky gel on skin after removal of plaster. The solid 
polymer-drug matrix gel with PG to NMP ratio of 2:1 showed smooth and dry surface 
and did not leave any debris behind upon removal of the plasters. The formulations 
with PG to NMP ratios of 3:1 and 4:1 produced solid polymer-drug matrix gel with 
viscous surface. Although these plasters were viscous and adhered strongly to the skin, 
they left viscous gel on the skin after removal of the plasters. In summary, formulation 
with polymer concentration of 9%, polymer to cross-linking agent ratio of 1.5:1 and 
PG to NMP ratio of 2:1 seemed to show acceptable physical properties. 
B. Evaluation of rheological properties of polymer-drug matrix gels 
andbioadhesive properties of plasters 
1. Measurement of rheological behavior of gels 
1.1   The effect of polymer concentration 
All the formulations with different polymer concentrations showed that G′ values were 
higher than G″ values and loss tangent values were less than 1. Moreover, loss tangent 
values were not influenced by the frequency of oscillation, indicating that all the gels 
were cross-linked gels and the network of the cross-linked gels would not change with 
oscillation frequency. The lowest value of loss tangent was obtained from the gel with 
the highest polymer concentration of 13% and the highest value of loss tangent was 
obtained from the gel with 5% of polymer (Figure 5). The loss tangent was negatively 
and significantly correlated with the concentration of polymer used (Pearson’s 
correlation, p<0.05).  
 
1.2 The effect of polymer to cross-linking agent ratio 
All the values of G′ were higher than those of G″ and the values of loss tangent were 
less than 1 for all the formulations with different ratios of polymer to cross-linking 
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agent. The loss tangent values were relatively independent of the frequency of 
oscillation. The lowest loss tangent was obtained from the strongest cross-linked gel 
formulation with polymer to cross-linking agent ratio of 1:1.5 and the highest loss 
tangent was obtained from the weakest cross-linked gel formulation with polymer to 
cross-linking agent ratio of 2.5:1 (Figure 6). The loss tangent was negatively and 
significantly correlated with the amount of cross-linking agent in the ratio of polymer 
to cross-linking agent (Pearson’s correlation, p<0.05). 
 
1.3 The effect of PG to NMP ratio 
The G′ values obtained from the plasters with different ratios of PG to NMP were 
higher than those of G″. The values of loss tangent were less than 1 and were not 
influenced by the frequency of oscillation. The lowest value of loss tangent was shown 
with the highest PG to NMP ratio of 4:1 and the highest loss tangent was seen with the 
lowest PG to NMP ratio of 1:2 (Figure 7). The loss tangent was negatively and 
significantly correlated with the PG (Pearson’s correlation, p<0.05). This indicated that 
the loss tangent was decreased with increase in the proportion of PG in the plaster 
formulations. In summary, the values of G′ were higher than the values of G″ for all 
formulations, indicating that all gels showed elastic behaviors. The loss tangent values 
were less than 1 and were independent of oscillation frequency, indicating that all the 
gels had elastic, cross-linked network structures. The formulation variables studied 
exerted different effects on the rheological/mechanical properties of the plasters as 


























































Figure 5. Comparison of dynamic moduli and loss tangent values among the 

























































Figure 6. Comparison of dynamic moduli and loss tangent values among the 
plasters with polymer to cross-linking agent ratios of 2.5:1 (•), 2:1 (▲), 1.5:1 (∗), 
























































Figure 7. Comparison of dynamic moduli and loss tangent values among the 
plasters with PG to NMP ratios of 1:2 (◦), 1.5:1 (∗), 2:1 (▲), 3:1(∙) and 4:1 (■) 
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2. Tensile testing for in vitro bioadhesion 
Among the plasters with different polymer concentrations, the highest detachment 
force was obtained from the plaster containing 9% of polymer. Plasters with the other 
polymer concentrations showed lower detachment forces (Figure 8a). 
 
For the plasters with varying ratios of polymer to cross-linking agent, the highest 
detachment force was seen with the plaster with the polymer to cross-linking agent 
ratio of 1.5:1. At other ratios, the plasters showed lower detachment forces (Figure 8b). 
 
Among the plasters with various ratios of PG to NMP, the highest detachment force 
was shown by the plaster with ratio of 2:1 and the plasters with other ratios showed 
lower detachment forces (Figure 8c). 
 
3. Adhesion study of aspirin plasters in pigs 
Table 5 shows the adhesion scores among different variables of the formulations on 
different days of assessment. It was found that plaster formulated with 9% polymer 
showed 90% adhesion to the skin. This was due to the bioadhesive nature of the 
polymer, which was employed in an appropriate amount for adhesion onto the skin for 
at least 8 h. At 11% and 13% polymer concentrations, % surface adhesion was 
decreased to 75% and 50% respectively. The optimal ratio of polymer to cross-linking 
agent was found to be 1.5:1 as it produced the maximum % surface adhesion (90%). 
Increasing proportion of polymer (2.5:1 and 2:1) gave lower % of surface adhesion 
(<50% and <75%) and increasing proportion of cross-linking agent (1:1 and 1:2) gave 
<90% and <75% of surface adhesion. It was found that an appropriate proportion of 
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Figure 8. Comparison of adhesion of plasters in terms of detachment force (◆) 
obtained from in vitro tensile testing and adhesion scores (■) obtained from in 
vivo visual analogue scale measurements 
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Table 5. Comparison of adhesion scores among different types of formulation on 
different days of assessment[a]
Day of assessment Formulation 
variables 
0 2 4 6 8 12 14 
Polymer concentration       
5% 3 3 3 3 3 3 3 
7% 2 2 2 2 2 2 2 
9% 0 0 0 0 0 0 0 
11% 1 1 1 1 1 1 1 
13% 2 2 2 2 2 2 2 
Polymer to cross-linking agent ratio     
2.5:1 3 3 3 3 3 3 3 
2:1 2 2 2 2 2 2 2 
1.5:1 0 0 0 0 0 0 0 
1:1 1 1 1 1 1 1 1 
1:2 2 2 2 2 2 2 2 
PG to NMP ratio      
1:2 2 2 2 2 2 2 2 
1.5:1 1 1 1 1 1 1 1 
2:1 0 0 0 0 0 0 0 
3:1 1 1 1 1 1 1 1 
4:1 1 1 1 1 1 1 1 
[a]Adhesion of plasters was scored by visual scoring scale method: 
0 = 90% adhered (essentially no lifting off the skin) 
1 = 75% to < 90% adhered (some edges only lifting off the skin) 
2 = 50% to < 75% adhered (less than half of the system lifting off the skin) 
3 = <50% adhered but not detached (more than half the system lifting off the skin       
without falling off) 
4 = patch detached (patch completely detached from the skin) 
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The higher proportions of PG (3:1 and 4:1) showed <90% adhesion of the plasters. In 
higher NMP proportions (1:2 and 1:1.5), surface adhesion were lowered to <75% and 
<90%. The results obtained from in vitro bioadhesion studies of plasters with different 
polymer concentrations, polymer to cross-linking agent ratio and PG to NMP ratio 
were consistent with those obtained from the in vivo adhesion studies (Figure 8). In 
conclusion, the plaster formulated with 9% polymer, polymer to cross-linking agent 
ratio of 1.5:1 and PG to NMP ratio of 2:1 had the greatest bioadhesive properties. 
 
C. HPLC assay 
The mobile phase was chosen after several trials with methanol, acetonitrile and 
phosphate buffer in various proportions and at different pH values. A mobile phase 
consisting of 70% phosphate buffer of pH 2.6 and 30% acetonitrile (v/v) was selected 
to achieve complete separation and maximum sensitivity. Flow rates between 0.5 and 
1.5 ml/min were studied. A flow rate of 1.0 ml/min gave the optimal signal-to-noise 
ratio with a reasonable separation time. Using reversed-phase C18 column, the retention 
times for aspirin and salicylic acid were found to be 3.1 and 4.2 min respectively. The 
maximum absorption of aspirin and salicylic acid occurred at 230 nm and this 
wavelength was chosen for the analysis. 
 
Five different concentrations of aspirin and salicylic acid were assayed using HPLC 
for plotting the standard curves of aspirin and salicylic acid (Figures 9). Linear plots 
were obtained for concentrations of 1−5 µg/ml of aspirin and salicylic acid by linear 
regression analysis. The standard error of slope and intercept of aspirin were 286.46 
and 94.62. The standard error of slope and intercept of salicylic acid were 1206.64 and 
398.54. The precision of the method (intra-day and inter-day variations of 
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determinations) was checked by repeating three times of each concentration of aspirin 
and salicylic acid. As shown in Table 6, the intra-and inter-day variations for aspirin 
and salicylic acid were less than 3%, indicating that the analytical method developed 
was accurate and precise for aspirin and salicylic acid. The limit of detection was 
calculated at signal to noise ratio of 3:1 and was 0.05 µg/ml for both aspirin and 
salicylic acid. The limit of quantitation was calculated at signal to noise ratio of 10:1. It 
was 0.1 µg/ml for aspirin and 1 µg/ml for salicylic acid. 
 68
(a)



































Figure 9. Standard calibration curves of (a) aspirin and (b) salicylic acid 
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1.05 ± 0.03 2.20 
 
1.02 ± 0.09 1.19 
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2.03 ± 0.04 1.20 
 
1.97 ± 0.11 2.01 
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2.96 ± 0.03 0.40 
 
3.06 ± 0.10 0.88 
4 
 
3.93 ± 0.11 2.40 
 
3.89 ± 0.09 0.35 
5 
 
5.16 ± 0.09 1.40 
 
5.04 ± 0.13 1.09 
*Mean ± S.D. (n=3) 
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D. In vitro drug release and skin permeation studies 
1. In vitro release of aspirin  
1.1 The effect of polymer concentration 
The effect of polymer concentration on in vitro drug release is shown in Figure 10. The 
highest release rate of aspirin was achieved with 5% polymer concentration. The 
lowest release rate of aspirin was achieved from the highest polymer concentration of 
13%. The amounts of drug released from the plasters with different polymer 
concentrations were significantly different (two-way ANOVA; p<0.05) and the 
amounts of drug released at different sampling times were also significantly different 
(two-way ANOVA; p<0.05). 
 
All the release profiles were linear when plotted against the square root of time (Figure 
11), indicating that drug release was determined by diffusion mechanism and the 
synthetic membrane did not pose as a permeation barrier to aspirin and salicylic acid. 
The release rates obtained from the slopes of the best fit lines were plotted against 
polymer concentration (Figure 12). Release rate decreased with increasing polymer 
concentration (p<0.05). 
 
1.2 The effect of polymer to cross-linking agent ratio 
The effect of ratio of polymer to cross-linking agent on the release of aspirin from the 
plasters is shown in Figure 13. The highest release of aspirin was achieved from the 
plaster with the least cross-linkage between polymer and cross-linking agent. The 
lower the proportion of cross-linking agent used, the higher was the drug release. The 
fraction released was significantly different (two-way ANOVA; p<0.05) among the 
 71
plasters with different ratios of polymer to cross-linking agent and at the different 
sampling times. 
The release profiles showed linear relationships with the square root of time (Figure 
14). The release rates obtained from the slopes of these linear curves were plotted 
against the ratio of polymer to cross-linking agent (Figure 15). Release rate decreased 
with increasing proportion of cross-linking agent (Pearson’s correlation, p<0.05).  
 
1.3 The effect of PG to NMP ratio 
As shown in Figure 16, the higher release rates of aspirin were achieved from the 
plaster with PG to NMP ratios of 1:2 and 1:1. The lowest release rate of aspirin was 
observed for the plaster with ratio of 4:1. The fraction released was significantly 
different among the plasters with different ratios of PG to NMP (except 1:2 and 1:1) 
and significantly different at different sampling times (two-way ANOVA; p<0.05). 
The released fraction of aspirin from the plaster with PG to NMP ratio of 1:1 is 
comparable with that of ratio of 1:2, showing that the higher proportion of NMP in the 
ratio of PG to NMP had no effect on the release rate of aspirin. 
 
When the drug release was plotted against the square root of time, a linear relationship 
was obtained (Figure 17). The release rates obtained from the slopes of the linear 
curves were plotted against the ratio of PG to NMP (Figure 18). Release rate decreased 
with increasing proportion of PG used in the plaster formulation (Pearson’s 
correlation, p<0.05). Table 7 shows the results obtained from Pearson’s correlation, 
indicating that drug release decreased with an increase in polymer concentration, 
proportion of cross-linking agent and proportion of PG (Pearson’s correlation, p<0.05). 


























Figure 10. The effect of polymer concentrations of 5% (), 7% (■), 9% (▲), 11% 


















Figure 11. The correlation of fraction of aspirin released from plasters with 
polymer concentrations of 5% (), 7% (■), 9% (▲), 11% (¯) and 13% (∗) with 













































Figure 13. The effect of polymer to cross-linking agent ratios of 2.5:1 (), 2:1 (■), 


















Figure 14. The correlation of fraction of aspirin released from plasters with 
polymer to cross-linking agent ratios of 2.5:1 (), 2:1 (■), 1.5:1 (▲), 1:1 (∗) and 
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Figure 15. The effect of polymer to cross-linking agent ratio on release rate of 


























Figure 16. The effect of PG to NMP ratios of 1:2 (), 1:1 (■), 2:1 (▲), 3:1 (∗) and 


















Figure 17. The correlation of fraction of aspirin released from plasters with PG to 
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Table 7. Pearson's correlation of polymer concentration, polymer to cross-linking 
agent ratio and PG to NMP ratio with drug release through synthetic membrane 
Variables Pearson's correlation R p-value 
Polymer concentration -0.59 0.35 <0.05 
Polymer to cross-linking agent 
ratio 
-0.57 0.33 <0.05 
PG to NMP ratio -0.52 0.27 <0.05 
 
 79
2. Study of aspirin permeation through pig abdominal skin 
2.1 The effect of polymer concentration 
Figure 19 shows the effect of polymer concentration on permeation of aspirin through 
pig skin. The highest permeation rate was shown by the formulation with the lowest 
concentration of polymer. Cumulative amounts of drug permeated through pig skin 
from the plasters with different polymer concentrations were significantly different 
(two-way ANOVA; p<0.05) and also significantly different among different sampling 
times (two-way ANOVA; p<0.05). The amounts permeated showed a linear 
relationship with square root of time (Figure 20) and was negatively and significantly 
correlated with polymer concentration (Pearson’s correlation, p<0.05) (Figure 21). It 
was indicated that the cumulative amount of aspirin permeated through pig skin 
decreased with increase in polymer concentration. 
 
2.2 The effect of ratio of polymer to cross-linking agent 
The effect of ratio of polymer to cross-linking agent on the permeation of aspirin 
through pig abdominal skin is shown in Figure 22. The highest amount of aspirin was 
permeated was found for a plaster with the lowest concentration of the cross-linking 
agent. The cumulative amounts of drug permeated through pig skin for the plasters 
with different ratios of polymer to cross-linking agent were significantly different at 
different sampling times (two-way ANOVA; p<0.05). The permeation results were 
linearly related to square root of time (Figure 23) and the permeation rate was 
negatively and significantly correlated with the proportion of cross-linking agent 
(Figure 24, Pearson’s correlation, p<0.05). 
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2.3 The effect of ratio of PG to NMP 
The higher proportion of PG in formulation decreased the amount of aspirin permeated 
through pig skin (Figure 25). The cumulative drug permeation through pig skin for the 
plasters with different ratios of PG to NMP was significantly different at different 
sampling times (two-way ANOVA; p<0.05). The cumulative amount of aspirin 
permeated is linearly related to the square root of time (Figure 26). The permeation 
rate of aspirin was negatively and significantly correlated with the proportion of PG 
(Pearson’s correlation, p<0.05). The permeation rate decreased with increase in 
proportion of PG (Figure 27). 
 
The cumulative amount of drug permeated through pig skin was negatively and 
significantly correlated with the polymer concentration, the proportions of cross-
linking agent and PG (Pearson’s correlation, p<0.05). Among them, the ratio of PG to 
NMP had the greatest effect on the permeation of the drug through pig skin (Table 8) 
whereas the polymer concentration had the greatest effect on aspirin release through 
synthetic membrane (Table 7). 
 
3. Comparison of flux of aspirin through different types of barriers 
Three types of barriers including synthetic membrane, pig skin and human abdominal 
skin were used for in vitro permeation studies. Figure 28 shows that the cumulative 
amount of aspirin permeated increased in the following order: synthetic membrane > 
human skin ≈ pig skin. The pig skin and the human skin showed similar permeability 
to aspirin, indicating pig skin resembled human skin in terms of drug permeability, 
particularly for aspirin. This further confirmed that the synthetic membrane did not 







































Figure 19. The effect of polymer concentrations of 5% (), 7% (■), 9% (c), 11% 


































Figure 20. The correlation of cumulative aspirin permeation through pig skin 
from plasters with polymer concentrations of 5% (), 7% (■), 9% (▲), 11% (∗) 
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Figure 21. The effect of polymer concentration on permeation rate of aspirin 







































Figure 22. The effect of polymer to cross-linking agent ratios of 2.5:1 (), 2:1 (■), 
1.5:1 (▲), 1:1 (∗) and 1:1.5 (◦) on cumulative amount of aspirin permeated 







































Figure 23. The correlation of cumulative amount of aspirin permeated through 
pig skin from plasters with polymer to cross-linking agent ratios of 2.5:1 (), 2:1 
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Figure 24. The effect of polymer to cross-linking agent ratio on permeation rate of 






































Figure 25. The effect of PG to NMP ratios of 1:2 (), 1:1 (■), 2:1 (▲), 3:1 (∗) and 
































Figure 26. The correlation of cumulative amount of aspirin permeated through 
pig skin from plasters with polymer to cross-linking agent ratios of 1:2 (), 1:1 
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Figure 27. The effect of PG to NMP ratio on permeation rate of aspirin through 
pig skin 
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Table 8. Pearson's correlation of polymer concentration, polymer to cross-linking 
agent ratio and PG to NMP ratio with cumulative drug permeated through pig 
skin 
 
Type of variables Pearson's correlation R p-value 
Polymer concentration -0.47 0.22 <0.05 
Polymer to cross-linking agent 
ratio 
-0.47 0.22 <0.05 






































Figure 28. The comparison of aspirin permeation through synthetic membrane 
(), pig skin (■) and human skin (▲) using the aspirin plaster formulated with 
polymer concentration of 9%, polymer to cross-linking agent ratio of 1.5:1 and 




E. Accelerated stability testing 
Figure 29 shows that there was no significant change in drug content of aspirin plasters 
after storage in the accelerated stability test conditions, indicating aspirin was stable in 
the plasters. There were no changes in physical properties of the plasters. Therefore, 
the aspirin plasters were stable for clinical usage. 
 
F. Skin irritation studies 
1. Visual scoring of skin irritation  
After application of placebo and aspirin plasters with different formulations for 14 
days, the test sites of the skin were assessed visually and scored according to visual 
analogue scoring system. There was no significant change in visual score before and 
after application of control and aspirin plasters. 
 
2. Assessment of skin irritation by laser Doppler perfusion imager 
2.1. The effect of polymer concentration on skin blood flow  
As shown in Figure 30, both placebo plasters and aspirin plasters showed higher skin 
blood flow results when 5% or 7% of polymer were used, compared to 9%, 11% or 
13% of polymer. Skin blood flow results of aspirin plasters and placebo plasters were 
significantly different for aspirin and placebo plasters with different polymer 
concentrations and also significantly different on different days of assessment (two-
way ANOVA; p<0.05). The paired t-test showed that there was a significantly higher 
skin blood flow due to aspirin plasters than placebo plasters for all polymer 




































2.2 The effect of polymer to cross-linking agent ratio 
Figure 31 shows that the skin blood flow results were higher for the placebo and 
aspirin plasters with polymer to cross-linking agent ratios 1:2 and 1:1 than those with 
ratios of 2.5:1, 2:1 and 1.5:1 after 14 days of application. The skin blood flow results 
for aspirin and placebo plasters were significantly different at different ratio of 
polymer to cross-linking agent and also significantly different on different days of 
assessment (two-way ANOVA; p<0.05). The skin blood flow results of aspirin plasters 
were significantly higher than those of the corresponding placebo plasters (paired t-
test, p<0.05). 
 
2.2 The effect of PG to NMP ratio 
Figure 32 shows that the skin blood flow results of both placebo and aspirin plasters 
were higher for PG to NMP ratios of 1:2, 3:1 and 4:1 than those with ratios of 1.5:1 
and 2:1 after 14 days of application of plasters. The skin blood flow results of both 
aspirin and placebo plasters were significantly different at different ratios and on 
different days of assessment also (two-way ANOVA, p<0.05). The skin blood flow 
results of placebo plasters were significantly lower than those of the corresponding 
aspirin plasters (paired t-test, p<0.05). 
 
3. Effects of aspirin concentration and duration of application of plasters on 
skin irritation 
Table 9 demonstrates that higher VAS scores were observed with higher aspirin 
concentrations and longer duration of application of aspirin plasters. The plasters with 
aspirin concentration of 200 mg showed no irritation on day 0. Minimal erythema was 
observed on day 2 and day 4. On day 6 and day 8, erythema and minimal edema were 
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observed. Erythema and edema were detected on day 12 and day 14. For the plasters 
with aspirin 300 mg, no irritation was seen on day 0. Minimal erythema was observed 
on day 2 and erythema and minimal edema were detected on day 4. On day 6, 8 and 
12, erythema and edema were detected. Definite edema was observed on day 14. The 
plasters with the highest aspirin concentration of 400 mg showed no irritation on day 
0. On day 2, erythema and minimal edema were observed. On day 4, erythema and 
edema were detected. On day 6 and 8, definite edema was observed and erythema, 
edema and papules were detected on day 12 and 14. Figure 33 shows that the highest 
cutaneous blood flow was seen with the plasters with the highest aspirin concentration 
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Figure 30. The effect of polymer concentration on LDPI values of (a) placebo 
plasters and (b) aspirin plasters on different days of assessment: day 0 (□), day 2 
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Figure 31. The effect of polymer to cross-linking agent ratio on LDPI values of (a) 
placebo plasters and (b) aspirin plasters on different days of assessment: day 0 
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Figure 32. The effect of PG to NMP ratio on LDPI values of (a) placebo plasters 
and (b) aspirin plasters on different days of assessment: day 0 (□), day 2 (▒), 
day 4 (▤), day 6 (▥), day 8 (▨), day 12 (▦) and day 14 (■) 
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Table 9. Visual scores of skin irritation of plasters with aspirin concentrations of 
200, 300 and 400 mg on the different days of assessment* 
 
*0 = No evidence of irritation 
Days of Aspirin concentrations 
Assessment 200 mg 300 mg 400 mg 
0 0 0 0 
2 1 1 2 
4 1 2 3 
6 2 3 4 
8 2 3 4 
12 3 3 5 
14 3 4 5 
 1 = Minimal erythema, barely perceptible 
 2 = Definite erythema, readily visible; minimal edema or minimal papular response 
 3 = Erythema, edema 
 4 = Definite edema 
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Figure 33. The effect of aspirin concentrations of 200 (□), 300 (▥) and 400 mg 
(■) and duration of application on LDPI values of plasters formulated with 9% 






A. Formulation of aspirin plaster 
Topical application of aspirin preparations is a better alternative to oral administration 
with respect to the avoidance of unwanted side-effects of aspirin associated with oral 
administration. The chemical properties of aspirin, such as low polarity, low melting 
point, low molecular weight and lipophilicity, make it a good candidate for 
percutaneous delivery. It was reported that aspirin has a good permeability through the 
skin (McAdam et al., 1995). However, overcoming the high water sensitivity of aspirin 
is a big challenge for the formulator. A non-aqueous system is suitable for preparation 
of topical aspirin to prevent hydrolysis of aspirin in aqueous medium to inactive 
degradation products. Although few studies (King, 1993; De Benedittis et al., 1992; 
Kassirer and King, 1988; Balakrishnan et al., 2001) with aspirin/solvent solutions have 
been reported, the use of organic solvents, such as chloroform, diethyl ether and 
dichloromethane, was not suitable for long-term clinical usage. The aim of the current 
study was to develop a formulation of non-aqueous bioadhesive plaster for 
percutaneous delivery of aspirin. A stable and non-irritating plaster was formulated 
and composed of a monolithic matrix in which aspirin was dissolved. It was supported 
by a non-woven cotton wool backing layer and covered by a plastic release liner. The 
release liner was removed just before the application of the plaster on the skin. 
 
It is well known that polyacrylate polymers have good bioadhesive properties and are 
widely used in the design of transdermal drug delivery systems. However, there are 
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very few bioadhesive polymers suitable for the development of the non-aqueous 
plasters. The polymers used for this purpose should meet some requirements, including 
solubility in water and solvents, gel forming property, bioadhesive property and 
reaction with cross-linking agent to form a three-dimensional network. According to 
the preliminary study, the copolymer of N-vinylacetamide and sodium acrylate was 
found to be suitable for the formulation of aspirin plaster. PNVA exhibits not only 
non-ionic property of its monomer of N-vinylacetamide but also weak anionic 
characteristic of its monomer of sodium acrylate. This renders the polymer some 
typical properties. It is weakly anionic and readily soluble in water, glycerin and 
various solvents, such as alcohols and aqueous ethanol solution. In the presence of 
trivalent ions, the polymer is cross-linked and forms an elastic hydrogel. The hydrogel 
formed is capable of holding a large amount of solvent within the microcavities of its 
three-dimensional network structure, which is a favorable feature for high drug 
loading. The polymer molecules in the cross-linked structure still possess their 
bioadhesive properties but are not as sticky as the uncross-linked counterpart. 
Moreover, the nonionic property of the polymer makes it resistant to pH changes and 
the presence of salts. Therefore, its viscosity is resistant to skin acidic pH and to salt 
from perspiration. In addition, the cross-linked polymer is also resistant to acidic drugs 
such as aspirin and an excess of aluminum salt during preparation. The hydrophilic 
nature of this polymer reduces the likelihood of skin irritation. These desirable 
properties of PNVA make it possible to formulate a bioadhesive non-aqueous delivery 
system containing a water-sensitive drug at a high dose. Solvents, such as PG, NMP 
and glycerin, were used in fabricating the aspirin plaster. These solvents are less 
volatile and aspirin was found to have a good solubility in the solvent mixture. The 
drug can be entrapped in the matrix network and a high loading of aspirin can be 
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achieved. Moreover, PG and NMP were reported to be penetration enhancers for some 
drugs (Aungst et al., 1986). Therefore, the combination of PG and NMP was expected 
to increase the permeation of aspirin through skin. 
 
Non-woven cotton wool was used as a backing layer in this formulation of aspirin 
plaster. The soft and smooth texture of cotton wool is suitable for application on skin 
surface and its flexibility also allow easy application on any part of body surface area. 
It can hold the adhesive polymer matrix tightly even when the plaster is stripped from 
the skin. A plastic release liner was used for the aspirin plaster. Its transparent 
appearance made the aspirin plaster cosmetically acceptable. It is easily removed from 
the plaster prior to application. Therefore it is a suitable release liner for packaging. 
 
B. Physical properties of polymer-drug matrix gels 
Different combinations of polymer, cross-linking agent and solvents were studied in an 
attempt to prepare a suitable plaster for clinical application. Depending on the 
combination, the plasters showed differences in appearance and texture of polymer-
drug matrix gel. Polymer-drug matrix gels consisting of lower polymer concentrations 
of 5% and 7% were wet and viscous due to the relatively higher content of solvents. 
Viscous gel residues were left on the skin surface upon removal of plasters. Such 
plasters are cosmetically unacceptable. Polymer-drug matrix gels with higher polymer 
concentrations of 11% and 13% were rigid with hard and rough surface and could not 
adhere to the skin surface for prolonged periods. In the formulation of polymer-drug 
matrix gels, a lower concentration of the cross-linking agent produced weakly cross-
linked gels which appeared sticky and wet, leaving behind sticky residues on the skin 
surface after removal of the plasters. With higher concentration of the cross-linking 
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agent, the strongly cross-linked gels made plasters inflexible leading to poor 
bioadhesion on the skin. When altering the ratio of PG to NMP, a higher proportion of 
PG resulted in very viscous polymer-drug matrix gel which was cosmetically 
unacceptable. With a lower proportion of PG, the gel was less viscoelastic and the 
plaster was less bioadhesive.  
 
1. The rheological properties of aspirin gels 
The rheological parameters and the shape of rheograms were directly related to the gel 
strength of the plasters (Madsen et al., 1998). Therefore, the rheological properties of 
the polymer-drug matrix gels were determined and effects of formulation variables on 
the gel structure were investigated. The results obtained from the rheological studies 
showed that G′ values were greater than G″ and loss tangent values were less than 1 
over the entire frequency range for all aspirin gel formulations. Loss tangent values 
were relatively independent of oscillatory frequency in all formulations of aspirin gel. 
These were consistent with the typical behavior of cross-linked gels, indicating that all 
the polymer-drug matrix gels had real three-dimensional network structures. However, 
the gel strength was a function of formulation variables as shown by the changes in the 
values of loss tangent with formulation variables including polymer concentration, 
polymer to cross-linking agent ratio and PG to NMP ratio. 
 
The effect of the polymer concentration on the viscoelastic properties of the polymer-
drug matrix gels was assessed. It was found that the polymer concentration was 
negatively and significantly correlated with the loss tangent values (Pearson’s 
correlation, p<0.05), indicating that higher polymer concentrations produced stronger 
cross-linked gels. The formulations with polymer concentrations of 11% and 13% 
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formed very hard cross-linked gels whereas the formulations with polymer 
concentrations of 5% and 7% formed weaker cross-linked gels. For formulations with 
lower concentration of polymer, the higher proportion of solvents accounted for the 
viscous properties of the gels. There have been several reports of the effects of the 
concentration of hydrophilic polymers on the viscoelastic properties of pharmaceutical 
formulations (Jones et al., 1996; 1997; 1998 and Talukdar et al., 1996) and the 
increased elasticity was associated with increasing polymer concentration. 
 
The ratio of polymer to cross-linking agent influenced the cross-linking density of the 
plaster and subsequently the loss tangent values. The amount of cross-linking agent 
was negatively and significantly correlated with loss tangent values (Pearson’s 
correlation, p<0.05). The higher proportion of cross-linking agent in gels with polymer 
to cross-linking agent ratios of 1:1 and 1:1.5 caused stronger cross-linking between 
polymer and cross-linking agent and produced stronger gels formed. For polymer to 
cross-linking agent ratios of 2.5:1 and 2:1, there was insufficient cross-linking agent, 
resulting in the formation of a weaker cross-linked gel. The optimal ratio of polymer to 
cross-linking agent was found to be 1.5:1. Therefore, it could be postulated that 
appropriate proportions of polymer and cross-linking agent were essential for 
preparing a strong, elastic and cross-linked gel to carry therapeutic amounts of drug.  
 
With respect to the ratio of PG to NMP, the proportion of PG was negatively and 
significantly correlated with loss tangent values (Pearson’s correlation, p<0.05). This 
indicated that loss tangent decreased with increase in the proportion of PG. Therefore, 
the higher proportion of PG in the solvent mixture formed the more viscoelastic 
polymer-drug matrix gel and thus increased gel strength. For lower proportion of PG, 
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the gel was less viscoelastic and it produced weak bioadhesive plaster for skin. 
Therefore, PG to NMP ratio of 2:1 was the most suitable for the preparation of an 
acceptable and stable plaster.  
 
2. In vitro and in vivo bioadhesion studies 
The results obtained from the in vitro tensile testing and in vivo adhesion studies 
showed that the formulations with 9% polymer concentration exhibited the highest 
detachment force and strongest bioadhesive properties. At lower polymer 
concentrations of 5% and 7%, less than 50% and less than 75% adhesion respectively 
were observed because their resultant gels were rather liquid-like leading to decreased 
cohesiveness and lack of adhesiveness of the plasters. With higher polymer 
concentrations of 11% and 13%, the increased polymer concentration caused the 
stronger and harder gel plasters but adhesiveness of the plasters decreased. Hence, it 
was concluded that 9% polymer content was optimal for the preparation of strong and 
bioadhesive plaster. 
 
The maximum bioadhesion was found to be associated with the formulation with 
polymer to cross-linking agent ratio of 1.5:1. A lower bioadhesion was obtained from 
the plasters with polymer to cross-linking agent ratios of 2.5:1, 2:1, 1:1 and 1:2. The 
plasters with ratios of 2.5:1 and 2:1 did not contain enough cross-linking agent for 
complete interaction with the polymer molecules. Therefore, the cohesiveness as well 
as adhesiveness of plasters decreased. With increasing the amount of the cross-linking 
agent in the formulations, the cross-linking density of the gels was increased up to a 
maximum. Maximal bioadhesion was achieved by the formulation with polymer to 
cross-linking agent ratio of 1.5:1. At its optimal ratio, polymer molecules were 
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completely cross-linked and yet possessed some functional groups of the polymer 
molecules for bioadhesion. Higher amounts of cross-inking agent (1:1 and 1:2) 
adversely affected the availability of these functional groups, thus bioadhesion 
decreased. Therefore, an optimal ratio of polymer to cross-linking agent (1.5:1) was 
important for strong bioadhesion of the plasters. 
 
For PG to NMP ratios of 1:2 and 1:1, the gels formed were solid in nature and 
bioadhesion strengths were lower. With PG to NMP ratio changing from 3:1 to 4:1, the 
higher contents of PG increased the viscoelastic properties of the gels but the 
adhesiveness of plasters was decreased. The best ratio of PG to NMP was found to be 
2:1, where the plasters showed the highest detachment force and maximum 
bioadhesion strength. The results obtained from in vitro and in vivo adhesion studies 
showed that a formulation with 9% polymer, polymer to cross-linking agent ratio of 
1.5:1 and PG to NMP ratio of 2:1 had ideal bioadhesive property suitable for clinical 
testing although the plasters prepared did not have the strongest viscoelastic properties. 
In contrast, the plasters with the strongest viscoelastic property, formulated with 
polymer concentration of 13%, polymer to cross-linking agent ratio of 1:1.5 and PG to 
NMP ratio of 4:1 did not have sufficient bioadhesion to be applicable for use in 
clinical testing. 
 
C. In vitro release and permeation studies 
1. Release of aspirin from the plasters 
The results from the in vitro drug release study showed that the highest rate of drug 
release was from formulation with the lowest polymer concentration while the slowest 
rate of drug release from the formulation with the highest polymer concentration. The 
 103
concentration of the polymer in the formulations was negatively and significantly 
correlated with the amount of drug released. This was attributed to the denser gel 
structure with increasing polymer concentration and thus the rates of aspirin release 
decreased. The plasters consisting of a lower concentration of polymer had loose gel 
network, therefore the drug was released easily from such type of gels. 
 
The amount of cross-linking agent was negatively and significantly correlated with the 
drug release rate. This indicated that a higher cross-linking density between polymer 
and cross-linking agent caused a decrease in rates of drug release from the plasters. 
When the amount of cross-linking agent was increased to a certain value, the polymer 
molecules were almost completely cross-linked and strong dense gels were formed. 
Higher cross-linking density produced smaller cavities in the gel matrices of the 
plasters and therefore, the release of drug dissolved in the solvents, which were 
entrapped in the cavity of the cross-linked gel, was slowed down. In contrast, if the 
amount of polymer was much higher than the amount of cross-linking agent, there was 
an abundance of the polymer that was not completely cross-linked and a weak gel was 
formed. Therefore, the drug was easily released from the bigger cavity of the weakly 
cross-linked gels.  
 
A high concentration of PG in the plasters caused a slow release rate of aspirin. This 
can be explained by the increased viscoelasticity of the gel containing large amount of 
PG (Rafee-Tehrani and Mehramizi, 2000; Chi and Jun, 1991 and Larrucea et al., 
2001). PG was not only a good co-solvent for the drug but it also can act as a 
penetration enhancer by altering the skin structure. It permeates the skin readily and 
carries the drug along with it (Squillante et al., 1998). Although PG is widely used as a 
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cosolvent for lipophilic drugs and has the potential to be a skin permeation enhancer, a 
higher proportion of PG decreased the amount of drug released. Therefore, an 
appropriate quantity of PG should be used. NMP enhances the permeation of lipophilic 
drugs by increasing their solubility in the skin (Akhter and Barry, 1985). It was 
reported that NMP enhanced the permeation of mefanamic acid across rabbit skin 
(Naito et al., 1985). However, an excess amount of NMP might produce dermatitis due 
to defattening of the epidermis after prolonged or repeated contact with excess amount 
of NMP (Barry, 1987). Therefore, the amount of NMP to be used in the plasters should 
be limited to a level that is non-irritating and safe for topical application. The results 
obtained from our studies showed that PG to NMP ratio of 2:1 was optimal in 
considering the release and permeation properties as well as the potential irritation. 
 
Overall, the percentage of aspirin released from the plasters was linearly related to the 
square root of time, indicating that the drug release was controlled by the diffusion of 
the drug through the tortuous routes made up of the microcavities in the three 
dimensional gel networks. 
 
2. Permeation studies with pig skins 
Although there are significant anatomical and biochemical differences between human 
and animal skins at cellular levels, animal skins are frequently used for in vitro 
permeation studies. Rat, guinea-pig, snake, pig and mouse skins are commonly used 
instead of human skin. Among them, pig skin showed the strongest resemblance to 
human skins (Wu et al., 1997). Therefore, in the permeation studies, pig skin was used 
as permeation barrier. For the optimal formulation, the permeation of aspirin through 
the excised human skin was also compared to that through the pig skin. 
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 The results obtained from the in vitro release studies were consistent and permeation of 
aspirin through the pig skin decreased with increasing polymer concentration and 
increasing the cross-linking density of the plaster (Pearson’s correlation, p<0.05). A 
higher level of drug release from the plaster resulted in faster permeation rate of 
aspirin through the pig skin. Increasing the PG to NMP ratio also decreased the 
permeation of aspirin through the pig skin. However, the change in the ratio of PG to 
NMP had a greater effect on the permeation of aspirin through the pig skin than 
through the synthetic membrane. This might be attributed to the enhancement effects 
of PG and NMP on the skin.  
 
In summary, the results obtained from in vitro drug release and permeation studies 
indicated that plasters formulated from low polymer concentration, low proportion of 
cross-linking agent and low proportion of PG showed the highest amount of drug 
released from the plasters and the highest amount of drug permeated through the pig 
skins. However, the physical properties of these plasters were unsuitable for clinical 
use. Therefore, plasters formulated with 9% of polymer, polymer to cross-linking 
agent ratio of 1.5:1 and PG to NMP ratio of 2:1 were chosen for clinical use because of 
their good physical properties, strong bioadhesiveness and moderate drug release and 
permeation rates through the pig skins. 
 
3. Comparison of flux of aspirin through various types of barriers 
The permeation of aspirin from the optimal plaster through different barriers was 
compared. The release of aspirin through the synthetic membrane was much higher 
than its permeation through the pig and human skins (ANOVA, p<0.05). The 
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permeation of aspirin through the pig skin and human skin were not significantly 
different (p>0.05), indicating that the pig skin resembled the human skin. It was 
reported by other research workers that excised human breast skin had no significant 
difference compared with the pig skin (Wu et al., 1997). Therefore, pig skin is suitable 
for substituting human skin in in vitro skin permeation and in vivo irritation studies. 
The synthetic membrane used was very porous, with pore size of 0.45 µm. It acted as a 
physical support and did not constitute a permeation barrier compared to the pig and 
human skins. Therefore, the amount of drug permeated through pig and human skin 
were significantly lower than that through the synthetic membrane (ANOVA, p<0.05).  
 
It was found that aspirin released from the plaster was linearly related to the square 
root of time. Aspirin has been reported to have good skin permeability (McAdam et 
al., 1995). Therefore, it can be postulated that overall permeation of aspirin through the 
skins was controlled by the drug released from plaster. The diffusion-controlled system 
is favorable for development of aspirin plaster in that the permeation and subsequent 
clinical performance is easily modified by changing the formulation. 
 
D. Accelerated stability testing 
The mixture consisting of PG and NMP was used to formulate the non-aqueous gel 
plaster. After storage under accelerated stability test condition (40°C, 75% RH) for 4 
weeks, there were no significant changes in appearance of the plasters and drug 
content. These findings indicated that aspirin was stable in the non-aqueous solvents, 
PG and NMP. The non-aqueous environment is the critical factor for preventing water-
sensitive drugs like aspirin from hydrolysis. 
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E. Skin irritation studies 
In this study, VAS and laser Doppler perfusion imager were used to assess skin 
irritation. VAS is a very useful simple method to assess the skin irritation qualitatively 
by the naked eye and LDPI is an additional tool to assess skin irritation quantitatively 
by measuring skin blood flow. Therefore, both assessment methods are complementary 
in the study of skin irritation. The higher cutaneous blood flow was found in site of the 
skin applied with the plasters formulated with 5% and 7% polymer concentration than 
that of the site of the skin applied with the plasters formulated with 9%, 11% and 13% 
of polymers for both aspirin and placebo plasters. The lower concentration of polymer 
formed semisolid plasters with higher proportion of PG and NMP which caused the 
skin irritation effect after prolonged contact with skin, leading to increased cutaneous 
blood flow. For both placebo and aspirin plasters, higher cutaneous blood flow were 
observed for formulations with polymer to cross-linking agent ratios of 1:1 and 1:2 
than those with ratios of 2.5:1, 2:1 and 1.5:1. This was due to the presence of higher 
proportion of the cross-linking agent, aluminum chloride. Prolonged contact with 
higher proportion of aluminum chloride caused the skin irritation effect and therefore 
increased the skin blood flow. Higher cutaneous blood flow was also observed for 
plasters with PG to NMP ratios of 1:2, 3:1 and 4:1. Prolonged contact of higher 
proportion of penetration enhancers (either NMP in 1:2 or PG in 3:1 and 4:1) increased 
dryness of skin and led to increased cutaneous blood flow. Using the VAS method, all 
the results showed no changes in skin color after application of aspirin and placebo 
plasters. The increase in the cutaneous blood flow was not sufficient to change the skin 
surface color. Another reason is the natural pink color of pig skin, which was quite 
difficult to differentiate between skin irritation and normal skin color. Therefore, LDPI 
was more sensitive than VAS in the assessment of skin irritation. A recent study 
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demonstrated that LDPI results did not correlate with VAS in irritant reaction in 
human (Goon et al., 2004). 
 
Aspirin itself also caused skin irritation in pig skin. Using plasters with different 
concentrations of aspirin (200, 300 and 400 mg), higher values of LDPI and VAS were 
seen with the higher concentrations of aspirin after application for 14 days. The 
increase in irritation was a function of the concentration of aspirin and the duration of 
application of the plaster. Therefore, the aspirin load is limited for the percutaneous 
delivery device. Duration of application of plaster also played an important role to 
achieve a safe and effective therapeutic action. The longer the application, the higher 
the extent of drug penetrated into the skin. Prolonged occlusion of the skin would 
make it soft and more prone to breakage of the barrier. The surface area of application 
of plaster also influenced the penetration of the drug. The larger surface area of 
application of plaster allows the higher amount of drug absorbed, thus leads to higher 
systemic availability and higher risk of adverse effects. Therefore, proper guidance is 
necessary for the application of topical plasters to adjust the duration, surface area and 
concentration of drugs to prevent the unwanted side effects.  
 
F. Limitations of our study 
There are some limitations of the study to be mentioned. 
1. Measurement of aspirin and salicylic acid levels in the skin after plaster application 
should be performed to compare with the levels of aspirin and salicylic acid in 
plasma. 
2. A larger sample size will be more sensitive to detect any statistical significant 
difference in skin irritation on pigs. 
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3. A clinical trial in healthy human subjects should be done to assess the safety 
profile and irritancy of the aspirin plasters in humans. 
4. After obtaining results in healthy humans it would be of prime importance to 
evaluate the efficacy and adverse effects of the formulation in patients suffering 
from itch and painful neuropathies such as post herpetic neuralgia and acute herpes 
zoster. 
5. Other methods of assessment of irritancy which have not been performed in this 
study such as measure of transepidermal water loss using evaporimeter should be 







1. Copolymer of N-vinylacetamide and sodium acrylate (PNVA) has good 
solubility in various solvents, such as PG, NMP, ethanol, and possesses good 
bioadhesive property. It can be cross-linked with trivalent ions to form an 
elastic gel. Hence, it is suitable for formulation of non-aqueous bioadhesive 
gels. 
2. Non-aqueous aspirin gels consisting of PNVA cross-linked with aluminum 
chloride in a mixture of PG, NMP and glycerin were successfully prepared by a 
casting method. The resultant polymer-drug matrix gels were soft, flexible, 
transparent and bioadhesive. The polymer-drug matrix gels consisted of a 
three-dimensional network where aspirin dissolved in the solvent mixture held 
in the microcavities of the structure. 
3. Formulation variables such as polymer concentrations, polymer to cross-
linking agent ratio and PG to NMP ratio greatly influenced the preparation 
process, physical and bioadhesive properties of the plasters, aspirin release and 
permeation through pig and human skins, and irritation to pig skin. 
4. Increasing polymer concentration increased the plaster mechanical strength but 
decreased drug release and permeation. Higher proportion of polymer and thus 
lower proportion of solvents in the plasters reduced irritation on pig skin. 
Maximum bioadhesion of the plasters was achieved with polymer 
concentration of 9%. 
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5. Increasing amount of cross-linking agent also increased the mechanical 
strength of the plaster but drug release and permeation were decreased. Higher 
amount of cross-linking agent caused skin irritation after prolonged period of 
contact with the skin. Polymer to cross-linking agent ratio of 1.5:1 showed the 
maximum bioadhesion. 
6. With increasing amount of PG, the mechanical strength of the plasters 
increased but drug release and permeation decreased. Irritation of pig skin also 
increased on prolonged contact with higher proportion of PG or NMP. 
Maximum bioadhesion of the plasters was produced by PG to NMP ratio of 
2:1. 
7. Aspirin itself also caused irritation to pig skin, particularly after a long period 
of application. Therefore, load of aspirin in the plasters and duration of 
application should be limited. 
8. Aspirin was stable in the plasters after storage under accelerated stability test 
conditions (40°C, 75% RH) for 4 weeks. The non-aqueous environment was 
crucial for preventing aspirin from hydrolysis. 
9. The plasters formulated with 9% of polymer, polymer to cross-linking agent 
ratio of 1.5:1 and PG to NMP ratio of 2:1 were found to be the most suitable 
for clinical use because of their good physical properties, strong 
bioadhesiveness, moderate drug release and permeation through human skins, 
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